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Abstract

TRANSFERRIN BINDING PROTEIN B STRUCTURE, FUNCTION, AND EXPORT IN
NEISSERIA GONORRHOEAE
By Meredith L. Weck
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University

Virginia Commonwealth University, 2012

Major Director: Cynthia Nau Cornelissen, Ph. D.
Professor of Microbiology and Immunology

Iron, an essential nutrient for most microorganisms, is sequestered in the host by ironbinding proteins, such as lactoferrin and transferrin. Neisseria gonorrhoeae utilizes transferrin
as an iron source and its iron acquisition system is composed of two transferrin binding proteins:
TbpA and TbpB. TbpA is a TonB-dependent, outer membrane transporter and TbpB is a
bilobed, surface exposed lipoprotein. TbpB can distinguish between apo- and holo-transferrin
which is involved in increasing the efficiency of iron uptake through the Tbps. It is anchored in
the outer leaflet of the outer membrane by its lipid moiety. We aimed to identify the mechanism
of TbpB export to the cell surface. No conclusions could be made from our results but we
identified a protein that could potentially be involved in lipoprotein transport. TbpB is a bilobed
protein with controversy over which lobe is involved in transferrin binding. In this study, we
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constructed a C-lobe deletion of TbpB to determine the role of the C-lobe in TbpB function.
Results presented here showed deletion of the C-lobe caused degradation of TbpB and the
minimal protein expressed was unable to bind transferrin both in vitro and in vivo. We were also
able to demonstrate the TbpB C-lobe deletion is able to support limited transferrin-mediated
growth, indicating some function of TbpB is retained. These results confirmed that both lobes
are necessary for wild-type function of TbpB.
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CHAPTER 1: Introduction

Neisseria gonorrhoeae was first identified as the causative agent of gonorrhea and named
by Albert Neisser in 1879. However, gonorrhea, meaning “flow of seed”, has been around since
well before that with many references throughout history, including the Bible (Leviticus 15) and
observations made by Hippocrates. The prevalence of gonorrhea has also led to the development
of several nicknames including “the drip” and “the clap”, from the French word clapoir, meaning
brothel. The advent of antibiotic therapy in the 1930s and ‘40s led to a rapid decrease in
gonorrhea prevalence. However, recent increases in sexually transmitted diseases as well as the
emergence of antibiotic resistance confirm the importance of further investigation into the
pathogenesis of this disease.

I. The Genus Neisseria
The family Neisseriaceae is comprised of the genera Neisseria, Moraxella,
Acinetobacter, and Kingella (101). They are classified as aerobic, Gram-negative bacteria and
are distinguished by their cell morphology as well as their ability to perform several biochemical
processes.
The genus Neisseria contains species that are normal flora and pathogens to humans and
animals. A number of biochemical tests are used to differentiate between them, including acid
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production, nitrate reduction, and the production of polysaccharide from sucrose. DNase,
oxidase, and catalase activities are also used to identify the species. These tests are also used to
differentiate Neisseria species from Moraxella and Kingella species (28, 101, 144). Neisseria
species have a diplococcus morphology with adjacent flattened sides and range from 0.6 to 1.5
m in size. The optimal growth conditions for Neisseria ranges between 35 and 37°C in the
presence of 5% CO2. Neisseria species colonize the mucous membranes of the nasopharynx,
eyes, and urogenital tract.
The genus contains two obligate human pathogens: N. gonorrhoeae and N. meningitidis.
Both species are facultative intracellular bacteria but N. meningitidis is the only Neisseria species
that produces an antiphagocytic capsule. While N. gonorrhoeae is never part of the normal flora,
N. meningitidis can be carried as normal flora of the nasopharynx. However, invasive
meningococcal disease can occur following colonization, for unknown reasons, causing bacterial
meningitis and meningococcemia. Although these pathogens are closely related, they cause very
different diseases and clinical manifestations.

II. Meningococcal Disease
A. Epidemiology
First described by Anton Weischselbaum in 1887, Neisseria meningitidis is a leading
cause of bacterial meningitis and other serious infections, causing significant morbidity and
mortality worldwide. Vieusseaux reported the first definitive identification of meningococcal
disease in 1805 when an outbreak occurred in Geneva, Switzerland (170, 187, 210). Since then,
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the different serogroups and genetic variability of the meningococcus have continued to allow
outbreaks of the disease.
Virulent N. meningitidis strains have a polysaccharide capsule that is used to classify
them into serogroups. Of the 13 serogroups that have been identified to date, only 5 (A, B, C,
W-135, and Y) are responsible for causing more than 90% of meningococcal disease worldwide
(35, 80). Additionally, serogroup X has recently been reported to cause a significant amount of
disease in sub-Saharan Africa (22, 79). Serogroup A is responsible for some of the largest, most
devastating epidemics that occur primarily along the “meningitis belt” in sub-Saharan Africa
every 8 to 10 years (73, 80). In the United States, serogroups B, C, and Y cause the majority of
the disease with each accounting for approximately one third of the cases (36).
Another important factor of meningococcal disease is that the etiological agent, N.
meningitidis, can be carried as a commensal. Approximately 10% of the population are carriers
of N. meningitidis with the highest rate of carriage in adolescents and young adults, and the
lowest in young children (34, 187). However, carriage is highly variable with some individuals
being carriers for many months while others are transient or intermittent carriers (80, 187, 242).
Rates of transmission and carriage increase in populations living in confined areas such as
college students and military personnel during epidemics (35, 187, 242).
B. Infection
Transmission occurs by person-to-person contact through the exchange of respiratory
droplets or saliva. Following colonization of the mucosal surfaces of the respiratory tract,
invasive meningococcal disease develops when the bacteria cross the epithelium and enter the
bloodstream causing meningococcemia. Symptoms include sudden onset of fever and a
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petechial or purpuric rash, and can result in hypotension, acute adrenal hemorrhage, multiorgan
failure, shock, and death (118, 170). The bacteria can also cross the blood-brain barrier resulting
in meningitis. Clinical manifestations include headache, fever, stiff neck, nausea, vomiting,
photophobia, and altered mental state (118, 170). Meningococcal meningitis is often
distinguished from other bacterial meningitis infections by the rash that is indicative of an
associated meningococcemia, although meningitis can develop independently (176). Symptoms
can appear quickly or develop 3-7 days after exposure. Long term neurological sequelae, such as
hearing loss, loss of limbs, mental retardation, and paralysis, can arise following a
meningococcal infection (118). Even with today’s medical advances and treatments, fatality
rates in industrialized nations range from 5 to 10% while fatality rates in developing countries
can reach up to 20% (230).
C. Treatment and Prevention
Since severe and debilitating symptoms can develop quickly, rapid diagnosis and
treatment is critical. Penicillin or ceftriaxone are the recommended treatments of meningococcal
disease even though some penicillin resistance has been reported (80, 188). For prevention,
there are two kinds of quadrivalent meningococcal vaccines available in the United States:
meningococcal polysaccharide vaccine (MPSV4) and meningococcal conjugate vaccine
(MCV4). Both kinds protect against serogroups A, C, Y, and W-135. There is currently no
vaccine against serogroup B. Available since the 1970s, MPSV4 contains purified
polysaccharide product and is the only licensed meningococcal vaccine for people older than 55
years of age but does not confer long-lasting immunity (36). MCV4 contains polysaccharide
conjugated to diphtheria toxoid and is the preferred vaccine for people ages 2 to 55 (36, 79).
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Despite having multiple vaccines and treatment options available, meningococcal disease
continues to be a global public health problem.

III. Gonococcal Disease
A. Epidemiology
Gonorrhea is the second most common reportable infection in the United States. In 2010,
309,341 cases were reported in the U.S. with a rate of 100.8 per 100,000 population, a slight
increase from the previous year (37). However, due to underreporting, the Centers for Disease
Control and Prevention estimates that this number is less than half the actual number of
infections which is greater than 700,000 (37). Global incidence of gonorrhea is estimated to be
62 million infected people annually (231).
Disparities in gonococcal infection rates exist among age, sex, ethnic, and socioeconomic
groups. Adults aged 20-24 years have the highest incidence of infections with rates in women
higher than in men (37). As in previous years, gonorrhea rates were highest in the South,
corresponding with the nation’s highest poverty rates, and among African Americans with rates 4
times the national average (37).
B. Infection
N. gonorrhoeae infects the non-ciliated epithelial cells of the mucosal membranes, with
the urethra in men and endocervix in women being the primary sites. Transmission occurs
through intimate sexual contact and ejaculation does not have to occur. Gonococcal infections in
men are typically symptomatic, occurring as an acute urethritis. Symptoms usually appear 1 to
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14 days after infection and include purulent discharge and dysuria. However, asymptomatic
infections can occur and serious complications, such as epididymitis, prostatitis, and infertility,
can develop if left untreated.
In women, N. gonorrhoeae infections generally present with no or mild symptoms, with
some estimates that up to 80% of infected women are asymptomatic. If symptoms emerge, they
occur within the first 10 days of infection and may consist of dysuria, urinary frequency,
increased vaginal discharge, and vaginal bleeding between periods. When left untreated, serious
complications can occur as a result of the ascension of the microorganism into the upper genital
tract and infection of the fallopian tubes and uterus. This causes pelvic inflammatory disease
(PID) which may lead to scarring of the fallopian tubes, ectopic pregnancy, and infertility.
Other sites that can be infected are the conjunctiva, pharynx, and rectal mucosa.
Anorectal infection in both men and women is usually asymptomatic but can present symptoms
of proctitis, including anal itching, discharge, soreness, bleeding, constipation, and painful bowel
movements (100). Throat infections are also usually asymptomatic but can cause a sore throat
and are an important reservoir of the gonococcus (232). Adult gonococcal conjunctivitis is
characterized by redness, burning or irritation, discharge, and inflammation of the eyes which, if
left untreated, can result in corneal scarring, perforation, and vision loss (134, 218). Neonates
can also contract gonococcal conjunctivitis through vertical transmission from the mother during
birth, resulting in similar symptoms (237).
Disseminated gonococcal infection (DGI) develops in approximately 0.5-3% of all
gonococcal infections. Classic symptoms include fever, dermatitis, and arthritis but rare, serious
complications can occur including endocarditis and meningitis (88). People infected with
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gonorrhea frequently are coinfected with Chlamydia trachomatis. Additionally, infection with
N. gonorrhoeae increases the transmission of HIV through the induction of viral RNA
expression (40) and increased shedding of HIV in semen (45) and cervical secretions (126) due
to inflammation.
C. Treatment
Effective antibiotic treatment is essential for the treatment and control of gonorrhea.
However, N. gonorrhoeae has developed resistance to almost all antibiotics used for treatment.
Sulfonamides were introduced as the first antimicrobial for treatment of gonorrhea in the mid1930s (97). The bacteria quickly became resistant to sulfa drugs with widespread resistance by
the mid-1940s (60). Fortunately, in 1943, penicillin was identified as highly effective against
gonococci and became the treatment choice for several decades (97, 119, 209). N. gonorrhoeae
began developing low level resistance to penicillin over the next 30 years due to the sequential
accumulation of chromosomal mutations (229). Additionally, high level plasmid-mediated
resistance was reported in several countries in 1976 (8, 150). Coincident with the development
of penicillin resistance, gonococci also developed resistance to several other antibiotics,
including aminoglycosides, macrolides, and tetracycline (206). Subsequently, fluoroquinolones,
such as ciprofloxacin, were recommended as the first line of therapy from the mid-1980s until
2007 when the CDC removed them from the recommended treatment regimen due to resistance
(38). Only one class of antimicrobials remains as the recommended and available treatment of
gonorrhea: the third generation cephalosporins (37). However, resistance to cephalosporins is on
the rise with the first high level clinical resistance identified in early 2011 (147). Gonococcal
infection does not elicit protective immunity so reinfection can occur, and there is no vaccine to
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prevent infection with N. gonorrhoeae. With no vaccine and diminishing treatment options,
gonorrhea may become untreatable.

IV. Gonococcal Virulence Factors
Neisseria possess a wide array of virulence factors, most of which are on the bacterial
cell surface. These outer membrane proteins play a role in cell colonization and invasion, as well
as evasion of the host immune response. Their ability to modulate these surface antigens through
phase and antigenic variation further enable the bacteria to cause infection, by modifying their
surface antigens and expressing factors based on environmental signals. Virulence factors are
essential for gonococcal pathogenesis and successful infection of the human host.
A. Pilus
The type IV pilus is an important virulence factor in N. gonorrhoeae and plays a role in
several key functions. Pili are filamentous cell surface structures that are comprised of two main
proteins, PilE and PilC. PilE is the major pilin subunit that polymerize into a helical cylinder to
form a filament 1,000-4,000 nm long and 6 nm in diameter (148). PilC is an essential assembly
factor at the base of the pilus (95), as well as an adhesion located at the tip (173).
The pilus is highly variable due to both antigenic and phase variation with a frequency of
about 10-3 per cell per generation (53). Antigenic variation results from the unidirectional DNA
recombination from silent gene copies (pilS) into the pilin expression (pilE) locus (75, 76, 129).
PilE also undergoes phase variation due to a poly-cytosine (C) tract located at the beginning of
the pilE gene that causes a frame shift during DNA replication, turning the gene on/off (102).
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Similarly, PilC is subject to phase variation but due to a poly-guanine (G) tract (95). Pilin can
also undergo post-translational modifications including glycosylation (211) and addition of a
phosphorylcholine (85).
The first step in bacterial infection is initial attachment to host cells which is mediated by
the pilus in neisserial infections (189, 196). Pili aid in overcoming the electrostatic repulsive
barrier between the gonococci and host cells (84) as well as adherence to the host cell surface.
Several potential receptors have been indicated to bind pili, including CD46 (96), C4 binding
protein (21), and complement receptor 3 (61). The importance of the pilus was demonstrated in
previous studies that showed only piliated gonococci were able to establish infection in human
males while non-piliated gonococci were unsuccessful (98). Pili also play a role in twitching
motility which is accomplished through filament retraction (128) and may provide a mechanism
by which non-motile gonococci can colonize and ascend mucosal surfaces (216). Additionally,
gonococci are naturally competent and pili play a role in the uptake of DNA, increasing the
transformation frequency of the gonococci (16, 184).
B. Opacity proteins
Opacity (Opa) proteins are a family of integral outer membrane proteins that function as
adhesins. Their name refers to the color and opacity changes of bacterial colonies observed with
expression of these proteins (197). Although they are expressed in greater number in pathogenic
Neisseria, some commensal Neisseria species are also capable of expressing Opa proteins (236).
The predicted structure of these proteins is comprised of four surface-exposed loops and eight
transmembrane domains (120). Opacity proteins are important virulence factors during
gonococcal infection because strains isolated from infected individuals are usually Opa+ (198).
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Additionally, Opa+ isolates were recovered from male volunteers that were inoculated with Opavariants (92).
N. gonorrhoeae can possess as many as 11 unlinked chromosomal alleles that encode
distinct Opa variants (13), while N. meningitidis only has 3-4 alleles (190). In the gonococci, up
to 4 Opas can be expressed at any given time due to high frequency phase variation (19). This is
due to slipped-strand mispairing during replication which causes variations in the number of
CTCTT repeats, resulting in a translational frame shift (138).
Opas are some of the proteins responsible for tight adherence of the bacteria to the host
cell surface after the initial attachment of the pili. Two host cell surface molecules have been
identified to bind Opas: heparin sulfate proteoglycans (HSPG) and carcinoembryonic antigenrelated cell adhesion molecules (CEACAMs). A subset of Opas bind HSPG, and vitronectin in
some cases, to activate bacterial cell uptake through several mechanisms dependent on the cell
type (68). However, most of the Opas bind CEACAMs to mediate invasion into cells such as
neutrophils (44). Binding of Opas to CEACAMs on epithelial cells causes cytoskeletal
rearrangements leading to internalization of the gonococci (72) and transcytosis across a
polarized monolayer (220). This interaction is significant because more than 95% of mucosal
and clinical isolates of meningococci and gonococci bind a CEACAM (212).
C. Porin
Porins are the most abundant outer membrane protein in the pathogenic Neisseria
species. They function as voltage-dependent aqueous pores for the exchange of ions and are
essential for bacterial survival (244). Porins form a predicted -barrel structure with eight
surface-exposed loops and assemble in the membrane as a trimeric complex (59, 207). While N.
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meningitidis expresses two types of porins, PorA and PorB, (64), N. gonorrhoeae only expresses
a PorB homolog (137). The gonoccocal PorB is further classified into two groups, PIA and PIB,
based on biochemical and immunological criteria (71).
Multiple roles in disease progression have been attributed to porin proteins, aiding in both
cell invasion and immune evasion. A unique feature of neisserial porins is their ability to
translocate into eukaryotic cell membranes (115, 223). They act as voltage-gated channels on
the target cell surface and are modulated by cytoplasmic ATP and GTP (174). PorB has been
found to cause target cell apoptosis by inducing a rapid calcium influx and activating calpain and
caspase activity (136). In addition, porins act as actin-nucleating proteins in epithelial cells,
facilitating cytoskeletal rearrangements and actin-mediated entry of the bacteria (224). Porins
have also been associated with inhibiting phagosome maturation in macrophages (135) as well as
neutrophil degranulation, opsonin receptor expression, and phagocyctosis (18). Serum resistance
is conferred by porins by down regulating both the classical and alternative complement
pathways by binding to the C4b binding protein and factor H, respectively (158, 159).
D. Lipooligosaccharide
Lipopolysaccharide (LPS) is the main component of the outer leaflet of the outer
membrane in Gram-negative bacteria. It contributes to the structural integrity of the membrane
and also acts as an endotoxin. LPS is comprised of a lipid A moiety that anchors LPS to the
membrane, a core domain of oligosaccharides that attach directly to the lipid A, and an Oantigen polysaccharide side chain. Neisseria produce a truncated version, lipooligosaccharide
(LOS), of this molecule that lacks the repetitive O-antigen side chains due to a highly branched
core oligosaccharide structure. During LOS synthesis, glycosyl transferases are responsible for
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the addition of sugar groups to the -chain. These transferases are subject to phase variation
which causes changes in the LOS size and structure, leading to antigenic variations of the LOS
(55). Poly-G tracts within the transferase genes are responsible for slipped strand mispairing and
the phase variation (241).
LOS can also undergo external modification by sialic acid modification. A gonococcusencoded sialyltransferase present in the outer membrane mediates sialylation using host-derived
cytidine 5’-mono-phospho-N-acetylneuraminic acid (CMP-NANA) as the sialyl donor (121,
140). The sialylation of LOS contributes to serum resistance by binding factor H and inhibiting
alternative complement pathway (160). However, the presence of sialic acid on LOS also
impairs cellular invasion into some cell types, suggesting that LOS variation may allow the
gonococci to fluctuate between invasive and serum-resistant phenotypes to promote bacterial
survival (208).
E. Reduction-modifiable protein
Reduction-modifiable protein (Rmp) is a surface exposed outer membrane protein that
exhibits a high degree of homology between strains (116). Rmp was named for the molecular
weight shifts observed after SDS-PAGE analysis in reducing conditions and shares partial
homology with the enterobacterial OmpA protein (69, 70). It is intimately associated with porin
and LOS in the gonococcal membrane (20, 86, 127). Antibodies generated against Rmp block
binding of antibodies against porin and LOS, inhibiting complement-mediated killing of the
gonococci (94, 165). This impairs the immune response and increases the host susceptibility to
infection (154).

13
F. IgA1 protease
Immunoglobulin A (IgA) is the predominant antibody on human mucosal surfaces and
pathogenic Neisseria secrete a serine protease specific to IgA1, an IgA subtype. This protease
cleaves IgA1 antibodies into the F(ab) and FC fragments which are involved in antigen binding
and effector function, respectively (153). The F(ab) fragment is thought to bind the bacterial cell
surface and coat antigenic determinants, blocking antibody binding sites and epitopes from the
immune system. IgA1 protease has also been demonstrated to cleave LAMP1, a major
membrane protein of late endosomes and lysosomes, promoting phagosomal escape and
intracellular survival of the gonococci (82, 112). The protease may furthermore play a role in the
traversal of epithelial barriers as it was shown to be involved in N. gonorrhoeae trafficking
across polarized epithelial monolayers (89). However, in a human challenge model, mutants
lacking IgA1 protease were indistinguishable from wild-type strains, indicating that it is not
involved in gonococcal colonization and establishment of infection in males (93). Thus, IgA1
protease likely only plays a role in immune evasion and intracellular survival of the bacteria.

V. Iron Sources and Transport in the Human Host
For most living organisms, iron is an essential nutrient that plays a pivotal role in many
growth and metabolic processes, including electron transport, DNA and amino acid synthesis,
and photosynthesis (219). Despite its abundance in the environment, the bioavailability of iron is
limited due to its physical properties. Under aerobic conditions, iron is primarily found in its
oxidized ferric form (FeIII), which is insoluble and aggregates into oxy-hydroxide polymers
(219). The more soluble, reduced form, ferrous iron (FeII), can react with reduced forms of
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oxygen, such as hydrogen peroxide, to generate free hydroxyl radicals by the Fenton reaction
(29). These cause oxidative stress leading to damage of cellular macromolecules, tissue injury,
and disease (221). Therefore, iron homeostasis is strictly regulated in the human body through
intracellular storage and carrier proteins.
A. Transferrin
Transferrin (Tf) is the most abundant iron transport protein in humans and plays a crucial
role in controlling free iron levels in the body as well as delivering iron to cells. It is a 80 kDa
monomeric glycoprotein that has two structurally similar domains, the N-terminal domain or Nlobe and the C-terminal domain or C-lobe. Each lobe is further divided into subdomains (N1 and
N2, C1 and C2) connected by a hinge that forms a deep, hydrophilic cleft for iron-binding (217).
Transferrin can theoretically bind two atoms of iron but it is only 30% saturated in the body and
preferentially binds iron in the N-lobe (235). It has a high affinity for iron with a binding
constant of 10-22 M (1) which is pH (39) and salt concentration dependent (234). Transferrin is
synthesized in the liver and secreted into the serum but is also found in other bodily fluids. It
transports iron from the gut to iron-depleted cells where it binds to transferrin receptors on the
cell surface. The whole complex is then internalized and transported to the endosome where a
decrease in the pH promotes iron release. Both the transferrin protein and transferrin receptor
are recycled to the cell surface.
B. Lactoferrin
Comparable to transferrin, lactoferrin is a single-chain, bilobed glycoprotein with a
molecular weight of about 80 kDa. The most abundant source of lactoferrin is milk but it is also
found in other bodily fluids, secondary granules of neutrophils, and on mucosal surfaces.
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Although the affinity of lactoferrin for iron is 300 times greater than transferrin, it is only 6 to
8% saturated in human milk (177). Lactoferrin’s antimicrobial activity has long been recognized
and attributed to its ability to sequester iron, making it unavailable to pathogens. However, a
secondary antibacterial mechanism has also been described that is independent of iron-binding
(30, 31, 63). It is mediated through the direct interaction between the pathogen and lactoferrin or
lactoferricins, derived peptides that are more potent than the intact protein (12, 63), which
disrupts the bacterial cell membrane (240). Lactoferrin also has a role in transcriptional
regulation (122), immunoregulation, and inhibition of tumor growth (31).
C. Ferritin
Ferritin is the primary intracellular iron storage protein in the human body and is present
in most cell types. Ferritins are a large class of ubiquitous iron storage proteins found in many
organisms including other vertebrates, invertebrates, plants, fungi, and bacteria (202). Ferritin is
a globular protein consisting of 24 subunits that forms a hollow protein shell with an iron core
that is capable of storing up to 4,500 FeIII atoms (81). It is composed of two kinds of subunits,
H and L, with molecular weights of 21 kDa and 19 kDa, respectively (7). By binding iron in its
ferric form, ferritin maintains it in a soluble, available form for use in cellular functions while
protecting the cell from the toxic effects of ferrous iron.
D. Heme binding proteins
Heme is a prosthetic group that consists of an iron atom in the center of a porphyrin ring.
It is involved in the function of many proteins with a diverse range of functions. Because of its
cytotoxicity, heme is rarely found in free form and is usually associated with hemoproteins such
as hemoglobin. Found in red blood cells, hemoglobin is a globular protein consisting of four

16
subunits, each with a heme group. Its main function is the delivery of oxygen and removal of
carbon dioxide throughout the body. Macrophages are mainly responsible for the metabolism of
hemoglobin by engulfing senescent erythrocytes (104) but at least 10% of red cell breakdown is
from intravascular hemolysis (66). Ruptured erythrocytes release hemoglobin and heme into the
plasma where its ability to catalyze hydroxyl-radical generation and cause oxidative stress is a
potential hazard (175). Additionally, nitric oxide, a critical regulator of vasodilation and
vascular homeostasis, reacts with hemoglobin in a fast, irreversible reaction, limiting the
bioavailability of nitric oxide (172). Therefore, efficient removal of free hemoglobin and heme
is essential and accomplished through the functions of two main proteins.
Haptoglobin is an acute phase plasma glycoprotein that binds to free hemoglobin,
protecting against its toxic effects. The haptoglobin-hemoglobin complex then binds to its
specific receptor, CD163, on macrophages, mediating endocytosis of the complex (104). After
internalization, the globin moieties are degraded in the lysosome, heme is converted into less
toxic compounds, and free iron is recycled (145). Hemopexin is another plasma glycoprotein
that protects against hemoglobin-mediated oxidative damage. When free heme is released in the
plasma during the breakdown of hemoglobin, hemopexin binds it and stimulates receptormediated endocytosis in the liver where the heme is degraded, similarly to haptoglobinhemoglobin (56). However, unlike haptoglobin, hemopexin is reutilized and returned intact to
circulation (183).
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VI. Iron Acquisition Systems in Bacteria
Iron homeostasis is so tightly regulated in the human body that there is virtually no free
iron. Withholding essential nutrients is an important line of defense against bacterial infection.
However, many bacteria have developed specialized mechanisms to obtain iron in the human
host, including siderophore production, organic acid utilization, and host-iron binding protein
receptors.
Many bacteria secrete siderophores, which are low molecular weight iron chelating
molecules. They have very high affinities for iron and can strip iron from host iron-binding
proteins. More than 500 different siderophores, produced by Gram-positive and Gram-negative
bacteria, yeasts, and fungi, have been described (161, 219). They are classified into three main
groups based on their chemical nature: hydroxyamates, catecholates, and hydroxyacids (62,
219). Some bacteria are also capable of producing hemophores which are functionally analogous
to siderophores except they target and remove heme from host hemoproteins (182).
After binding to iron, ferrisiderophore complexes are transported into the bacterial cell
through specific transport systems. In Gram-negative bacteria, these systems are dependent on
the TonB-ExbB-ExbD complex for energy and consist of an outer membrane receptor,
periplasmic binding protein, and ATP-driven transporters in the cytoplasmic membrane (62).
Siderophores produced by other microorganisms, xenosiderophores, may also be utilized as an
iron source through these transport systems.
In addition to siderophores, some microbes have the ability to take up iron from organic
acids like pyruvate and citrate (29). The ability to use citrate as an iron source has been noted in
several bacertia, including Shigella flexneri (114), N. meningitidis (6), and Escherichia coli (65).
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In E.coli, the best described ferric citrate transport system, the outer membrane receptor, FecA, is
necessary for ferric citrate uptake across the outer membrane (215). The transport system also
involves a periplasmic binding protein (FecB), two cytoplasmic membrane proteins (FecC and
FecD), and a membrane-associated ATP-binding protein (FecE) (186). It is dependent on the
TonB-ExbB-ExbD complex for energy (245) and is regulated by the presence of citrate and iron
(90).
Another method of iron acquisition is the utilization of host iron-binding proteins through
receptors on the bacterial cell surface. Receptors for these proteins, described below, have been
identified in many bacteria including Helicobactor pylori (91), Staphylococcus aureus (78), and
Haemophilus influenzae (179). This mechanism of iron acquisition is well characterized in
Neisseria and discussed in detail below.

VII. Iron Acquisition by Pathogenic Neisseria
Neisseria do not produce siderophores (227) but can utilize xenosiderophores aerobactin
(226) and enterobactin (33). N. gonorrhoeae can also use dihydroxybenzoylserine and
salmochelins (195). However, xenosiderophores are not available at all sites of infection and
their concentrations may not be sufficient to support growth. Therefore, Neisseria mainly rely
on their ability to utilize host iron-binding proteins transferrin, lactoferrin, and hemoglobin as
iron sources. Each iron-binding protein has its own specific receptors on the bacterial cell
surface but they are similar to each other, consisting of a TonB-dependent transporter and a
lipoprotein.
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The lactoferrin iron acquisition system consists of two components: lactoferrin binding
protein (Lbp) A and B. LbpA is a TonB-dependent outer membrane transporter (17) and LbpB
is a lipoprotein that, unlike LbpA, is not required for the utilization of human lactoferrin as an
iron source (14). However, due to a large deletion, only about 50% of clinical gonococcal
isolates express the Lbps (4). Neisseria are also able to use free heme and hemoglobin as iron
sources (130). No specific receptor has been identified for free heme but a two-component
system, HpuAB, has been identified for hemoglobin and hemoglobin-haptoglobin in both N.
gonorrhoeae and N. meningitidis (41, 42, 109, 111). In this system, HpuB is the TonBdependent outer membrane transporter and HpuA is the associated lipoprotein, both of which are
required for the utilization of hemoglobin. Additionally, a single component, TonB-dependent
hemoglobin iron transporter, HmbR, was found only in N. meningitidis (192, 193). Both of these
hemoglobin iron acquisition systems undergo phase variation due to a poly-G tract (41, 110,
166).
Most iron uptake systems are energy-dependent processes and require TonB-dependent
transporters. These systems rely on the TonB-ExbB-ExbD complex for this energy.
Cytoplasmic membrane proteins ExbB and ExbD are thought to harness the proton-motive force
that is generated across the cytoplasmic membrane. This energy is then passed to TonB which
spans across the periplasm, by an unknown mechanism, to physically interact with TonBdependent receptors in the outer membrane (99, 106, 131). This interaction causes a
conformational change in the transporter, resulting in the internalization of the substrate. The
TonB system in N. gonorrhoeae is essential for the utilization of host iron-binding proteins (48),
as well as xenosiderophores in strain FA1090 (87). The FbpABC system is responsible for
transporting iron extracted from lactoferrin and transferrin across the periplasm and into the

20
cytoplasm (43). However, the periplasmic binding protein and ABC transport system for iron
extracted from hemoglobin has not yet been identified.

VIII. Transferrin Iron Acquisition System of Neisseria
The acquisition of iron from transferrin in the pathogenic Neisseria is dependent on a two
component receptor complex. It is comprised of two transferrin binding proteins, TbpA and
TbpB. These proteins are encoded by a bicistronic operon with the tbpB gene located upstream
of tbpA (108, 169). The genes are co-transcribed but a 86 base-pair intergenic region between
the genes potentially forms a stem loop in the mRNA, resulting in differential expression of the
genes with a 2:1 ratio of tbpB transcripts to tbpA transcripts (169). The tbpBA promoter contains
a Fur (ferric uptake regulator) binding site, a global regulator that represses gene transcription in
the presence of iron (108, 203). Therefore, the Tbps are preferentially expressed under ironrestricted conditions and the presence of transferrin does not alter their expression (180, 181).
TbpA is an integral, outer membrane protein that forms a pore through which the iron is
translocated across the membrane (49). It is a TonB-dependent transporter with an N-terminal
TonB box, demonstrating homology to other TonB-dependent transporters (49). TonB
specifically interacts with TbpA (99) and a TonB box mutant is capable of binding transferrin
but defective in transferrin-iron uptake (48). TbpA is essential for the utilization of transferrin as
an iron source as mutants that do not express TbpA are capable of binding transferrin but
incapable of growing on it (49, 51). Recently, the crystal structure of N. meningitidis TbpA was
solved, confirming the previously hypothesized 22-strand transmembrane -barrel pore and an
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N-terminal plug domain (27, 146, 243). The TbpA protein is highly conserved among
pathogenic Neisseria strains (46).
The second component of the transferrin receptor complex, TbpB, is a surface exposed
lipoprotein (5, 108). Unlike TbpA, TbpB is not essential for transferrin-iron utilization (5) but is
capable of binding transferrin and distinguishing between apo- and holo-transferrin (26, 51). It is
thought that this ability, along with its ability to affect the association and dissociation of
transferrin (58), make the process of iron uptake more efficient. Gonococcal mutants lacking
TbpB are still able to bind transferrin but exhibit decreased iron uptake efficiency (5).
The unfolded TbpB protein is recognized and translocated across the inner membrane by
the Sec system through its N-terminal signal sequence (24). TbpB also contains a signal
peptidase II cleavage site and is able to be labeled with C14-palmitic acid, indicating that it is
lipid modified (5). It is fully surface exposed and tethered to the outer leaflet of the outer
membrane by its lipid moiety (57). However, the mechanism of TbpB transport across the
periplasm to the outer membrane and its localization to the outer leaflet of the outer membrane is
still unknown. Internal homology of neisserial TbpB indicates a bilobed structure with several
regions of identity between the N- and C-terminal halves (164). This was confirmed by the
resolution of the crystal structure of N. meningitidis TbpB (146). Controversy remains as to
whether only the N-lobe or both lobes are involved in binding transferrin and responsible for the
function of Neisseria TbpB.
Iron internalization from transferrin is initiated when a transferrin molecule binds to the
TbpA and TbpB receptor complex (Figure 1). TbpA is energized by the TonB-ExbB-ExbD
complex through an interaction with its TonB box. Iron is then stripped from transferrin,
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Figure 1. Schematic of the Neisseria transferrin iron acquisition system. Human transferrin
(Tf) can complex two atoms of iron. The transferrin iron acquisition system is composed of two
outer membrane (OM) proteins, transferrin binding protein (Tbp) A and B. TbpA forms the pore
through which iron enters into the cell and TbpB is a lipid modified accessory protein. Iron
internalization is an energy-dependent process which is supplied by the cytoplasmic inner
membrane (IM) complex TonB-ExbB-ExbD through a TonB-TbpA interaction. Once
internalized, iron is bound by the periplasmic chaperone FbpA and shuttled across the periplasm
(PP) to the FbpB-FbpC permease complex in the IM. In an ATP-dependent step, iron is
translocated into the cytoplasm.
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presumably through interactions with the TbpA plug domain, and translocated into the
periplasm. The periplasmic binding protein, FbpA, binds the iron and shuttles it across the
periplasm to the cytoplasmic membrane. Here, the FbpB-FbpC permease complex transports the
iron into the cytoplasm in an ATP-dependent step (Figure 1).

IX. Vaccine Development against N. gonorrhoeae
Vaccine development against N. gonorrhoeae has been challenging due to several
factors. The vaccine against N. meningitidis functions by eliciting bactericidal antibodies against
the polysaccharide capsule, which N. gonorrhoeae does not produce. Also, many potentially
antigenic surface exposed proteins, such as pilin and opacity proteins, are subject to phase and
antigenic variation. Despite its highly variable nature, pilus was evaluated as a vaccine candidate
with no success (25). Porin, although not subject to phase or antigenic variation, was also
unsuccessful as a vaccine candidate (228) due to LOS sialylation and Rmp antibodies blocking
potential bactericidal activity of porin antibodies (165).
The Tbps are promising vaccine candidates since they are not subject to high frequency
phase or antigenic variation, are fully surface exposed, and are expressed in all clinical isolates
(130). Additionally, it has been shown that they are necessary for the establishment of infection
in a human male challenge study (50). Meningococcal Tbps elicit antibodies that are
bactericidal, cross reactive against heterologous strains, and block transferrin utilization (152,
191, 225). However, it has been demonstrated that meningococcal TbpB alone is sufficient in
producing a protective immune response (113, 151, 152, 168). The protective role of TbpB has
also been confirmed in Moraxella cartarrhalis (139), Actinobacillus pleuropneumoniae (171),
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and Haemophilus influenzae (222). Also, recombinant gonococcal Tbps conjugated to cholera
toxin B subunit induced an antibody response in the serum and genital tract of female mice, with
TbpB generating a greater response than TbpA (156). Therefore, TbpB is a potential antigen for
the development of an efficacious vaccine against N. gonorrhoeae.

X. Objectives
Understanding the structure and function of TbpB is crucial in delineating its potential as
a vaccine candidate. TbpB is entirely surface exposed and tethered to the outer leaflet of the
outer membrane by its lipid moiety. However, little is known about the export of TbpB to and its
orientation in the outer membrane. First, we sought to identify the mechanism of TbpB transport
to the outer membrane and its localization to the outer leaflet of the outer membrane. We
employed mutagenesis using a transposon library to screen for deficiencies in transferrin
utilization and potential TbpB export deficient mutant strains.
TbpB has a bilobed structure, similar to human transferrin, and is able to bind transferrin
independently of TbpA. Previous studies analyzing transferrin binding showed differing results
with in vitro recombinant protein studies attributing only the N-lobe with binding and in vivo
studies with intact gonococci indicating the involvement of both lobes. Secondly, we wanted to
determine the role of the TbpB C-lobe in transferrin binding and iron stripping in vivo. This was
done through the generation and characterization of a TbpB C-lobe deletion protein in N.
gonorrhoeae strains. Identifying how the TbpB protein is exported to the outer leaflet of the
outer membrane and determining the regions of TbpB required for function in vivo could provide
insight into the pathogenesis of the organism and identify potential therapeutic targets.
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CHAPTER 2: Materials and Methods

I. Bacterial Growth Conditions
N. gonorrhoeae strains were maintained on GC medium base (GCB) (Difco) with
Kellogg’s Supplement I (98) and 12 M Fe(NO3)3 (Supplement II) at 37°C and 5% CO2. For
iron-depleted liquid growth conditions, gonococci were grown in a defined media that was
treated with Chelex 100 (Biorad) to remove any iron (CDM) (227). Additionally, iron-deplete
conditions were achieved by growth in GCB media containing Kellogg’s Supplement I. After
one mass doubling, Desferal (DFO) (50 M) was added to increase the iron stress. All liquid
cultures were grown at 37°C with 5% CO2 shaking at 220 rpm and allowed to grow for 4 hours
after Desferal addition. Iron-stress of plate-grown gonococcal strains was achieved by overnight
growth on GCB with Kellogg’s Supplement I and 5 M DFO (Sigma) plates followed by
resuspension in GCB media. E. coli strains were maintained on Luria Bertani agar plates and
grown in Luria Bertani (LB) media containing 100 g/ml of ampicillin for TOP10 cells and both
100 g/ml of ampicillin and 34 g/ml of chloramphenicol for the BL21 (pLysS) cells at 37°C
shaking at 225 rpm.
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II. Generation of Mutants using a Transposon Library
The transposon library was created by the laboratory of Dr. William Shafer at Emory
University and its construction is described later in Chapter 3. The transposon used to generate
the library contains a kanamycin resistance cassette. We used this library to transform
gonococcal strain MCV515 (Table 1) by the process of liquid transformation. Piliated gonococci
were suspended in GCB media with Kellogg’s Supplement I, Supplement II, and 5 mM MgCl2.
Cells were mixed with DNA from the transposon library and incubated for 30 minutes at 37°C
with 5% CO2. Fresh GCB/MgCl2 media was added and the mixture was incubated for an
additional 5½ hours. Gonococci were plated on GCB agar plates containing kanamycin (50
g/ml) to select for transposon insertion into the gonococcal genome and incubated for 18 hours
at 37°C with 5% CO2.

III. Screening Transposon Library Transformants
Single colonies from the liquid transformation of MCV515 with the transposon library
were patched onto CDM plates containing 30% saturated human transferrin (12.5 M) (CDMTf) and then onto GCB plates containing Kellogg’s Supplement I and Supplement II. Plates
were incubated at 37°C with 5% CO2 for 24 to 48 hours. Samples that were unable to grow on
the CDM-Tf plates were then passed from the GCB plate onto fresh GCB/Supplement
I/Supplement II plates. To ensure single colony purification, the transformants were colony
purified by streaking 8 single colonies onto GCB/Supplement I/Supplement II plates, continuing
this for a total of 4 passages. Subsequently, a single colony from each of the 8 passaged samples
was patched onto CDM-Tf plates, CDM plates containing 12 M Fe(NO3)3, and
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Table 1. Strains used in this study.
Strain
N. gonorrhoeae
FA19
FA6747
FA6815
FA6819
FA6905
MCV515
MCV516
MCV650
MCV829
MCV830
MCV833
FA19 ΔC
FA6747 ΔC
MCV515 ΔC
Mutant 4912
Mutant 11579
Mutant 13614
E. coli
TOP10

BL21 (DE3) pLysS

Phenotype (genotype)

Source

Wild type
TbpA- (tbpA::mTn3cat)
TbpA-, TbpB- (tbpB::)
TbpB- (tbpB251-708)
TbpB- (tbpB)
L9HA TbpA (tbpA∇HA)
L9HA TbpA, TbpB- (tbpA∇HA, tbpB)
TonB- (tonB::)
L9HA TbpA, HA4 TbpB (tbpA∇HA, tbpB∇HA)
L9HA TbpA, HA5 TbpB (tbpA∇HA, tbpB∇HA)
L9HA TbpA, HA8 TbpB (tbpA∇HA, tbpB∇HA)
TbpB C-lobe- (tbpB-708)
TbpA-, TbpB C-lobe- (tbpA::mTn3cat, tbpB-708)
L9HA TbpA, TbpB C-lobe- (tbpA∇HA, tbpB-708)
L9HA TbpA, NG2117- (tbpA∇HA, ng2117::km)
L9HA TbpA, ExbD- (tbpA∇HA, exbD::km)
L9HA TbpA, ExbD- (tbpA∇HA, exbD::km)

(130)
(49)
(5)
(5)
(51)
(242)
(242)
(77)
(57)
(57)
(57)
This study
This study
This study
This study
This study
This study

F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15
ΔlacΧ74 recA1 araD139 Δ(ara-leu) 7697 galU
galK rpsL (StrR) endA1 nupG λF- ompT hsdSB (rB-mB-) gal dcm (DE3)
pLysS (CamR)

Invitrogen

Novagen
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Table 2. Plasmids used in this study.
Plasmid
pCR2.1 TOPO
pET-22b(+)
pBluescript SKII(+)
pCR2.1 TOPO N-lobe
pCR2.1 TOPO
IGR/tbpA
pCR2.1 TOPO C-lobe
deletion
pET-22b(+) N-lobe
pUNCH403
pUNCH750
pUNCH755
pUNCH768
pUNCH769
pUNCH770
pUNCH 772
pVCU521
pVCU758

Relevant characteristics
KanR AmpR
AmpR
AmpR
pCR2.1 containing N-lobe segment of tbpB
amplified with oVCU677 and oVCU678
pCR2.1 containing IGR and tbpA segment amplified
with oVCU679 and oVCU680
pCR2.1 containing C-lobe deletion gene of ligated
tbpB N-lobe and IGR/tbpA segments
pET-22b(+) containing N-lobe segment of tbpB
amplified with oVCU711 and oVCU712
pBluescript SKII(+) containing mTn3(Cm) insertion
in tbpA sequence
pBluescript SKII(+) containing tbpB sequence from
Sau3AI site to Sau3AI site
pBluescript SKII(+) containing mTn3(Cm)
downstream of tbpA
pBluescript SKII(+) containing tbpB sequence from
Sau3AI site to AccI site
pBluescript SKII(+) containing tbpB sequence from
Sau3AI site to AgeI site
pBluescript SKII(+) containing tbpB sequence from
Sau3AI site to NheI site
pBluescript SKII(+) containing tbpB sequence from
Sau3AI site to BspMI site
pCR2.1 containing HA epitope insertion in loop 9 of
tbpA
pCR2.1 containing L9HA in tbpA and mTn3(Cm)
downstream of tbpA

Source
Invitrogen
Novagen
Stratagene
This study
This study
This study
This study
(49)
(47)
(5)
(47)
(47)
(47)
(47)
(242)
(Unpublished)
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GCB/Supplement I/Supplement II plates. Plates were incubated at 37°C with 5% CO2 for 24 to
48 hours and any sample that was unable to grow on CDM-Tf but able to grow on CDMFe(NO3)3 was further analyzed.

IV. Ligation-mediated PCR and DNA sequencing
To identify the site of the transposon insertion in the gonococcal genome, we performed
ligation-mediated polymerase chain reaction (LMPCR) as described previously (11, 149)
(Figure 2). The genomic DNA from transformants was digested with Sau3AI restriction enzyme
and a linker was ligated to the ends of the DNA fragments. The linker was formed by annealing
LMP1 with LMP2 (Table 3). The insertion sites were then amplified with Platinum Taq DNA
polymerase High Fidelity (Invitrogen) using LMP1 and IR1, an outward primer to the inverted
repeats of the transposon element (Table 3). PCR products were cloned into TOPO pCR2.1
vector (Invitrogen) and transformed into competent E. coli strain TOP10 (Invitrogen), following
manufacturer’s instructions. Plasmids were purified from overnight cultures using the Qiaquick
spin miniprep kit (Qiagen Sciences) and sequenced by the Nucleic Acids Research Facility at
Virginia Commonwealth University, using the provided M13 primers for the vector (Invitrogen).
Sequences were mapped to the genome of N. gonorrhoeae using nucleotide BLAST. Alignment
of the sequenced products with the FA19 genome sequence from the Broad Institute database
was completed using Vector NTi (Invitrogen).
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Figure 2. Schematic of Ligation-mediated PCR. The gonococcal chromosomal DNA was
digested with a restriction enzyme (step 1) and a linker was ligated onto the ends of the
fragments (step 2). The fragment containing the transposon insertion was then amplified by PCR
using primers to the linker and the inverted repeats of the transposon (step 3).
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Table 3. Oligonucleotides used in this study.
Oligonucleotide

Sequence (5’-3’)

LMPCR oligonucleotides a
LMP1
TAGCTTATTCCTCAAGGCACGAGC
LMP2
GATCGCTCGTGCCTTG
IR1
CCGGGGACTTATCAGCCAACC
C-lobe deletion oligonucleotides b
oVCU677
CTGGGCGGAGGCGGCAGTTTCG
oVCU678
AAGCTTTTAGCCGCTTGAAGCCGCCG
oVCU679
CCAAAAGCTTGTGAAATAAGCACGGC
oVCU680
GGCGTACTTGCTGCCGTCATCAACCG
oVCU711
CCCCCCCATATGCTGGGCGGAGGCGGCAGTTTCG
oVCU712
CCCGGATCCTTAGCCGCTTGAAGCCGCCGGAGCA
TTGCC
Gene specific primers
GC698
AACCTTCGTTATCGCGGCGGGTTTTCTGTTTTTTG
GCTTCTGGGTATCCAAC
oVCU136
ATGAACAATCCATTGGTGAATC
Tfbp26
CCCAAGTAACATAGCGGTGG
Tfbp30
CATCAATATTTTGGGCAAAA
Sequences encoding novel restriction enzyme sites are bolded
Nucleotides encoding the novel stop codon are italicized
a
Complementary sequences are underlined
b
Non-homologous nucleotides are underlined

Amplicon

Linker/Fwd
Linker
Rev

N. tbpB N-lobe Fwd
N. tbpB N-lobe Rev
IGR and tbpA Fwd
IGR and tbpA Rev
E. tbpB N-lobe Fwd
E. tbpB N-lobe Rev

tbpB C-lobe del.
Fwd
tbpB C-lobe del. Rev
tbpA L9HA Rev
tbpA L9HA Fwd
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V. Generation of the TbpB C-lobe deletion
A. Construction of the gonococcal TbpB C-lobe deletion gene
Deletion of the C-lobe of TbpB was generated by DNA splicing by directed ligation
(107) in which the DNA sequences located upstream and downstream of the gene segment to be
deleted are amplified and then ligated together (Figure 3). Primers were designed to the N-lobe
segment of the tbpB gene with the forward primer, oVCU677, beginning directly after the LSAC
lipidation sequence and the reverse primer, oVCU678, ending immediately before the start of the
C-lobe, based on the meningococcal TbpB crystal structure (Table 3). The reverse primer also
contained a stop codon followed by a HindIII restriction site at the 5’ end for the ligation
process. Primers were also designed to the intergenic region (IGR) and beginning of tbpA, with
the forward primer, oVCU679, starting immediately after the end of the tbpB gene which
encodes a native HindIII site (Table 3). The PCR products were ligated into TOPO pCR2.1
vector and transformed into competent E. coli strain TOP10. The transformants were screened
for the incorporation of the PCR products into the vector by lysis followed by agarose gel
electrophoresis and ethidium bromide (EtBr) staining. To confirm the correct orientation of the
PCR products, plasmids were purified using the Qiaquick spin miniprep kit, digested with
HindIII (New England Biolabs), and subjected to agarose gel electrophoresis. Purified plasmids
were also sequenced at the Nucleic Acids Research Facilities of Virginia Commonwealth
University to ensure expected gene sequence.
To isolate the desired plasmid fragments for ligation, the vectors containing the PCR
products were digested with the restriction enzyme HindIII (Figure 3). This released the PCR
product containing the N-lobe segment and the TOPO vector containing the IGR and tbpA

35

Figure 3. Schematic of DNA splicing by directed ligation. Primers were designed to the
regions upstream and downstream of the tbpB C-lobe segment (step 1). The primer to the 3’ end
of the N-lobe sequence of tbpB encoded a restriction enzyme site for HindIII. The 5’ end of IGR
of the tbp operon has an intrinsic HindIII restriction enzyme site. After PCR amplification, the
products were cloned into pCR2.1 TOPO vector (step 2). The plasmids were digested with
HindIII, generating the N-lobe PCR product and vector containing the IGR and tbpA with sticky
ends, and ligated together to create the C-lobe deletion tbpB gene (step 3).
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portion. These fragments were gel purified using the Qiaquick gel extraction kit (Qiagen
Sciences), according to manufacturer’s instructions, and the TOPO vector containing the IGR
and tbpA was treated with shrimp alkaline phosphatase (USB). The N-lobe fragment and DNA
ligase (Invitrogen) were added to the treated vector and incubated for 4 hours at 15°C.
Incorporation of the N-lobe segment into the vector containing the IGR and tbpA was again
confirmed by plasmid isolation and agarose gel electrophoresis. The proper orientation of the Nlobe fragment was determined by restriction enzyme digest with HindIII and EcoRI (New
England Biolabs), separately, and agarose gel electrophoresis.
B. Gonococcal transformation
A gonococcal uptake sequence needed for transformation is present in the IGR between
tbpB and tbpA. The properly ligated plasmid was purified, according to manufacturer’s
instructions (Qiagen Sciences), and linearized using KpnI (New England Biolabs). This plasmid
was then transformed into gonococcal wild-type FA19 strain by spot transformation.
Approximately 10 CFU of piliated FA19 were applied to a small area of a GCB plate and the
linearized plasmid was spotted on top of the gonococci. Transformation mixtures were
incubated at 37°C with 5% CO2 for 24 hours. Subsequently, single colonies were passed onto
additional GCB plates. Since there was no selectable marker for this transformation, a PCR
screen using primers GC698 and oVCU136 (Table 3) was employed to identify the
transformants that contained the desired deletion of the TbpB C-lobe.
To create TbpA mutations in the C-lobe deletion strain, we utilized previously made
plasmids to transform this strain. To generate a TbpA knockout strain, a plasmid containing a
chloramphenicol resistance cassette in tbpA (49) (pUNCH403; Table 2) was used to transform
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the TbpB C-lobe deletion strain by liquid transformation, detailed above. After liquid
transformation, gonococci were plated on GCB agar plates containing chloramphenicol (1
g/ml) to select for allelic exchange and incubated for 24 hours at 37°C with 5% CO2.
Transformants were streaked onto fresh GCB agar plates containing 1 g/ml of chloramphenicol
to confirm incorporation of the chloramphenicol resistance cassette. Inactivation of TbpA was
confirmed using SDS-PAGE and immunodetection with anti-TbpA antibodies as described
below. To generate a TbpA loop 9 HA epitope insertion mutant in the C-lobe deletion
background, we combined two previously constructed plasmids: pUNCH755 and pVCU521
(Table 2). pUNCH755 contains a chloramphenicol resistance cassette in the downstream region
of tbpA (5) which was cut out of the plasmid using XbaI restriction enzyme (New England
Biolabs). This was then ligated into the tbpA downstream region of pVCU521 plasmid, which
contains the HA epitope insertion in TbpA loop 9 (243), after its digestion with XbaI. The
ligated plasmid, pVCU758, was used for the liquid transformation of the TbpB C-deletion strain
and selection method described above. The HA insertion in loop 9 of TbpA was confirmed
using PCR with primers Tfbp26 and Tfbp30 (Table 3).
C. Construction of plasmid to express C-lobe deletion in E. coli
The tbpB N-lobe segment was PCR amplified from gonococcal strain FA19 genomic
DNA. The forward primer, oVCU711, contained a NdeI restriction enzyme site at the 5’ end and
additional nucleotides to aid in digestion (Table 3). The reverse primer, oVCU712, contained a
stop codon, BamHI restriction enzyme site, and additional nucleotides at the 5’ end (Table 3).
This PCR product consisted of the same sequence used in the construction of the tbpB C-lobe
deletion in N. gonorrhoeae. The pET-22b(+) expression vector (Novagen) and the PCR product
were digested with NdeI (New England Biolabs) and BamHI (New England Biolabs) and
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purified using the Qiaquick PCR purification kit (Qiagen Sciences). The PCR product and
vector were ligated together with DNA ligase, incubating at room temperature for 1 hour. The
ligated vector was transformed into TOP10 E. coli cells and plasmid was purified using the
Qiaquick spin miniprep kit. Incorporation and orientation of the N-lobe encoding gene was
confirmed by the digestion of the ligated plasmid with NdeI and BamHI, followed by agarose gel
electrophoresis. The resultant plasmid encoded the N-lobe segment of tbpB under the control of
a T7 promoter (Table 2). For expression of the recombinant TbpB protein, the plasmid was
transformed into the E. coli expression strain BL21 (DE3) (Novagen) which express T7 under
the control of the lac promoter and also carries the pLysS plasmid which produces T7 lysozyme
to reduce basal level expression of the recombinant protein.
D. Recombinant protein expression
Cultures of E. coli (5 mls) were grown for 16 hours at 37°C and shaking at 225 rpm in
LB broth containing 100 g/ml of ampicillin and 34 g/ml of chloramphenicol. One milliliter of
the starter culture was used to inoculate 100 ml of LB broth containing100 g/ml of ampicillin
and 34 g/ml of chloramphenicol. Cultures were shaken at 225 rpm at 37°C until they reached
an OD600 of 0.45-0.50. Two millimolar IPTG (isopropyl--D-thiogalactopyranoside) was added
to induce recombinant protein expression. One milliliter samples of the induced culture were
taken at 0, 1, 2, and 3 hours, and centrifuged. The pellet was solubilized with Laemmli
solubilizing buffer, standardizing to cell density, for subsequent SDS-PAGE and
immunodetection analysis.
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VI. Immunoblotting and Detection
A. Whole cell lysate preparation, SDS-PAGE, and protein transfer
Gonococcal strains were grown under iron-stressed conditions as described above.
Cultures were standardized to a constant cell number and centrifuged for 10 minutes at 13,000
rpm. Pellets were resuspended in Laemmli solubilizing buffer (105) and stored at -20°C. Prior
to use, -mercaptoethanol was added to 5%. Transposon mutagenesis samples were boiled for 3
minutes and the TbpB C-lobe deletion samples were heated for 2 minutes at 95°C. All samples
were threaded through a 28-gauge needle and subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) on 10% and 12% gels. Proteins were
transferred to nitrocellulose membrane (Whatman) in 20 mM Tris Base, 150 mM glycine, and
20% methanol in a submerged transfer apparatus (Biorad) at 28 mAmps for 16 hours.
B. TbpA detection
For detection of TbpA, the nitrocellulose membranes were blocked with 5% bovine
serum albumin (BSA) (Roche) in high-salt Tris-buffered saline (HS-TBS; 20 mM Tris base, 500
mM NaCl) and 0.05% Tween 20 (Sigma). Membranes were probed with polyclonal, TbpAspecific antiserum (49) and washed with HS-TBS with 0.05% Tween 20, followed by a
secondary goat anti-rabbit antibody conjugated to alkaline phosphatase (Biorad). Blots were
developed using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (Sigma) in
buffer containing 100 mM Tris (pH 9.5), 50 mM MgCl2, and 100 mM NaCl.
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C. TbpB detection
To detect TbpB, membranes were blocked with 5% non-fat dry milk (Biorad) in low-salt
TBS (LS-TBS) with 0.05% Tween 20 and probed with polyclonal anti-TbpB antibody (155).
Blots were washed with LS-TBS and 0.05% Tween 20, followed by probing with horseradish
peroxidase (HRP) conjugated goat anti-rabbit antibody (Biorad). Blots were developed using
Opti-4CN substrate kit developing system (Biorad) according to manufacturer’s instructions.
Alternatively, membranes were blocked with 5% non-fat dry milk in LS-TBS with 0.05% Tween
20 and probed with horseradish peroxidase conjugated transferrin (HRP-Tf) (Jackson
ImmunoResearch) as described previously (51). HRP was detected using ECL Plus western
blotting substrates (GE Healthcare or Pierce), according to manufacturer’s instruction, and
reactive bands were identified by exposure to film.
D. TonB detection
For TonB detection, blots were blocked with 5% non-fat dry milk in LS-TBS with 0.05%
Tween 20, probed with polyclonal antibody to TonB (99), and washed with LS-TBS and 0.05%
Tween 20. The primary antibody was detected with goat anti-mouse antibody conjugated to
HRP (Biorad) and developed with Opti-4CN substrate developing system.

VII. Protease Accessibility Assay
The protease accessibility of TbpB was performed as described previously (51). Ironstressed gonococci were grown in GCB liquid culture as detailed above and standardized to cell
density. They were treated with 2.5 g/ml trypsin (Bovine pancreatic, Sigma) for 0, 15, and 30
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minutes. Protease treatment was stopped by the addition of 0.6 trypsin-inhibiting units of
aprotinin (Sigma) and the treated cells were pelleted by centrifugation. The pellets were
resuspended in Laemmli solubilizing buffer, followed by the immunodetection of TbpB using
anti-TbpB antibody and HRP-Tf as specified above.

VIII. Whole-cell Binding Assays
Gonococcal strains were grown in liquid culture under iron-stressed conditions as
described above. The cultures were standardized to cell density, applied to nitrocellulose
membrane, and allowed to dry. Membranes were blocked with 5% non-fat dry milk in LS-TBS
with 0.05% Tween 20. To detect TbpB, blots were probed with polyclonal anti-TbpB antibody,
described above, and washed with LS-TBS and 0.05% Tween 20. Blots were then probed with
HRP conjugated goat anti-rabbit antibody (Biorad) and developed using Opti-4CN substrate
developing system, according to manufacturer’s instruction. For assessment of whole-cell Tf
binding, membranes were probed with HRP-Tf and washed with LS-TBS and 0.05% Tween 20.
HRP was detected by the Opti-4CN system.

IX. Transferrin Utilization Assays
Transferrin utilization was evaluated using CDM plates supplemented with 12.5 M of
30% saturated human transferrin. Ferric nitrate was used as a positive control for this assay and
added to CDM plates at a concentration of 12 M. Strains were streaked onto plates and
incubated at 37°C in a 5% CO2 atmosphere for 24 to 48 hours.
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X. Saturation of Human Transferrin
Apo human transferrin (Sigma) was resuspended in ferration buffer, pH 8.4 (100 mM
Tris, 150 mM NaCl, 20 mM NaHCO3) to a concentration of 10 mg/ml. Iron solution, pH 8.6
(100 mM NaCitrate, 100 mM NaHCO3, 5mM FeCl3) was added to achieve the saturation
percentages of 5, 10, 20, 30 and 50, and incubated for one hour at room temperature. The
ferrated transferrin solution was dialyzed at room temperature for 4 hours in a 200-fold volume
of dialysis buffer, pH 7.4 (40 mM Tris, 150 mM NaCl, 20 mM NaHCO3). The buffer was
changed and dialysis was allowed to proceed overnight at 4°C. These differentially saturated
transferrin samples were then used in transferrin utilization assays as described above.
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CHAPTER 3: Identification of the TbpB Transport Mechanism through
Transposon Mutagenesis

I. Introduction
The outer membrane of Gram-negative bacteria is comprised of proteins, phospholipids,
and LPS or LOS. There are two types of proteins in the outer membrane: lipoproteins that are
anchored to the membrane with a lipid tail and integral proteins that contain membrane-spanning
regions. These proteins, along with some periplasmic and inner membrane proteins, are
transported across the inner membrane through the general secretory pathway consisting of the
multi-subunit Sec machinery. The Sec translocase is responsible for the transport of unfolded
proteins into the periplasm, which occurs without compromising the general permeability of the
membrane (133). An N-terminal signal sequence targets proteins to the Sec system and is
removed after translocation. Distinct mechanisms exist for the localization of the proteins to
their final destination in the cell wall. These mechanisms have been extensively studied in E.
coli but remain largely uncharacterized in other Gram-negative bacteria.
First, there are two types of N-terminal signal sequences, signal I and signal II. Signal I
releases the protein into the periplasm where it can be secreted or inserted into the outer
membrane, most likely with the aid of a periplasmic chaperone (185). Signal II causes the
protein to be lipidated and anchored in the outer leaflet of the inner membrane (157). This signal
sequence contains a distinct region, known as the lipobox, that acts as a recognition site for
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cleavage and lipid modification. The consensus sequence for about three-fourths of all
lipoproteins in bacteria is Leu-(Ala, Ser)-(Gly, Ala)-Cys (83). The modification reaction
involves three steps: the addition of a diacylglycerol group to the sulfhydryl group of the
cysteine residue, cleavage of the signal peptide, and aminoacylation of the cysteine (178). The
mature lipoproteins formed through this process have a lipid-modified cysteine as the first
residue at the N-terminus.
Following the addition of a lipid moiety to the protein, sorting to the inner or outer
membrane occurs. This signal consists of the amino acids directly adjacent to the lipidated
cysteine. The inner membrane retention signal is an aspartate at position 2 of the protein (239).
However, it has also been demonstrated that the residue at position 3 can affect the localization
of a lipoprotein (67). Proteins with this signal are retained on the periplasmic side of the inner
membrane while proteins lacking this signal are transported to the outer membrane. Since lipid
modification occurs at the inner membrane, proteins are involved in binding to the hydrophobic
lipid tail of the lipoprotein and carrying it across the hydrophilic environment of the periplasm.
Bacterial lipoproteins have been shown to be involved in a variety of processes including
nutrient uptake, signal transduction, adhesion, transport, and antibiotic resistance. E. coli has
over 90 lipoprotein species, most of which are localized in the inner leaflet of the outer
membrane (141). The transportation of these lipoproteins is accomplished by the lipoprotein
localization (Lol) machinery, comprised of the inner membrane protein complex LolCDE, the
periplasmic chaperone LolA, and the outer membrane receptor LolB (Figure 2) (204, 205). LolC
and LolE are integral membrane proteins that form a complex with LolD, an ATPase, to act as an
ATP-binding cassette (ABC) transporter (238). This complex is responsible for recognizing
lipoproteins destined for the outer membrane and releasing them from the inner membrane
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Figure 2. Schematic of the Lol system in E. coli. The Sec system recognizes the N-terminal
signal sequence of lipoproteins and translocates them across the inner membrane (IM) in an
unfolded state. In the periplasm (PP), the signal sequence is cleaved, the lipid moiety is added,
and the protein is folded and inserted into the periplasmic side of the IM. Signal I proteins are
retained in the inner membrane and signal II proteins are recognized by the LolCDE complex.
Lipoproteins are released from the inner membrane and shuttled across the periplasm to the outer
membrane (OM) by LolA. LolA transfers the lipoproteins to the outer membrane receptor LolB,
which inserts them into the inner leaflet of the OM.

\
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to the periplasmic chaperone LolA (238). LolA, a lipoprotein-specific molecular chaperone,
forms a complex with a lipoprotein and shuttles it across the periplasm to the outer membrane
(123). Here, LolA transfers the lipoprotein to LolB, the outer membrane receptor that is
anchored to the outer membrane by its own lipid moiety (124). This transfer is energy
independent and presumably driven by the difference in affinity for lipoproteins between the two
proteins (124). LolB then inserts the lipoprotein into the inner leaflet of the outer membrane
through an unknown mechanism (141). Deletion of any of these proteins in E. coli is lethal (142,
199, 200).
The Lol system is well conserved in Gram-negative bacteria and Neisseria do have
LolABCD homologs (103, 201). Although there is no LolE homolog, LolC and LolE exhibit
considerable sequence similarity and LolC may function as a homodimer (23). However, the
contribution of the Lol system in lipoprotein transport in Neisseria has not been confirmed (214),
indicating different machinery may be responsible or a different mechanism of export exists.
Neither of these options has been identified and the method of lipoprotein transport to the outer
membrane remains unknown. Also, all known lipoproteins in E. coli face the periplasm (24)
while other mircoorganisms, such as Klebsiella (54), Bordetella (52), and Borrelia (74), also
have surface-exposed lipoproteins. Neisseria produce lipoproteins on the cell surface with TbpB
being fully surface exposed and anchored to the outer membrane only by its lipid moiety (57).
The mechanism of translocation of these lipoproteins across the outer membrane to be localized
in the outer leaflet is also unknown.
Neisserial TbpB has a lipobox sequence of LSAC with a leucine at the +2 position,
suggesting that it might be a substrate for an export process similar to the Lol system.
Additionally, transport to the outer membrane may be dependent on sequence-specific signals
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within the protein. Previous studies in our lab, done by Amanda DeRocco and Karen Ostberg,
analyzed the role of lipidation in the localization of TbpB to the outer membrane and
demonstrated that it is necessary for transport and surface exposure of the protein. Amanda
DeRocco generated a TbpB mutant where the lipoprotein signal II sequence (LSAC) was
changed to a signal I sequence (LAAA). She showed that although the non-lipidated protein was
able to bind transferrin by western blot, it did not bind transferrin at the cell surface, indicating
that it was not surface exposed (unpublished data). Karen Ostberg confirmed the LSAC TbpB
mutant was not lipidated through palmitic acid labeling and it was actually secreted (unpublished
data). These data indicate that without the lipid moiety, TbpB still enters the periplasm as a fully
functional protein but is not associated with the cell surface and is secreted into the extracellular
milieu. Although the non-lipidated TbpB protein is secreted, this does not rule out the possibility
of proteinaceous machinery being involved in the transport of lipidated proteins. Additionally,
translocation across the outer membrane to be anchored in the outer leaflet is expected to require
a large pore formed by a protein or protein complex.
In this study, we sought to identify the mechanism of TbpB transport to the outer
membrane and its localization to the outer leaflet of the outer membrane in N. gonorrhoeae. We
screened mutants generated using a transposon library, created by the laboratory of William
Shafer, for defects in human transferrin utilization. This library had been previously used to
identify gonococcal genes involved in the resistance to antimicrobial agents of the innate host
defense (11). We isolated three potential TbpB export deficient mutants and identified the
location of the transposon insertions in the genome of these mutants through LMPCR and DNA
sequencing. Finally, we analyzed the surface exposure of TbpB in these mutants using protease
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accessibility assays. If the export of TbpB was being affected by the transposon insertion, TbpB
would not be on the cell surface and the surface exposure of TbpB would be undetectable.

II. Results
A. Screening of transposon library revealed multiple potential TbpB export mutants
The transposon library was constructed by carrying out saturated mutagenesis in the
chromosomal DNA of gonococcal strain F62 using a transposon containing a kanamycin
resistance cassette with flanking Himar1 inverted repeats (11). The DNA was reintroduced into
the strain by natural transformation, and the chromosomal DNA from 10,000 colonies was
isolated to create the library (11). In order to screen for defects in TbpB transport to the outer
membrane, we utilized a previously created mutant, MCV515, that has a hemaglutinin (HA)
epitope in the loop 9 (L9) of TbpA. This mutant binds transferrin with wild-type affinity but can
utilize transferrin only in the presence of TbpB (243), which must be on the cell surface
(unpublished data). Therefore, if TbpB is not being transported to the cell surface, then the
gonococci will not be able to utilize transferrin as an iron source in this background strain. This
can be used to screen for potential TbpB export deficient transformants. The transposon library
was transformed into the MCV515 background and the growth phenotypes of the generated
mutants were examined on CDM-Tf plates. Any mutants that were unable to grow on transferrin
were then colony purified and retested on CDM-Tf and CDM-Fe(NO3)3 plates. The use of
CDM-Fe(NO3)3 was to determine if the mutation caused a CDM related growth defect or if it
was specific to the use of transferrin. Through this screening, several potential TbpB export
deficient mutants were identified: mutants 4912, 11579, and 13614. Their growth phenotypes
(Tf-negative and Fe(NO3)3–positive) were confirmed on CDM plates (Figure 5; mutant 13614

51

Figure 5. Growth phenotype of potential TbpB export deficient mutants on CDM plates.
Potential TbpB export deficient gonococcal mutants 4912 (A and B), 11579 (C and D), and
13614 (data not shown) were plated onto CDM medium containing either 30% saturated Tf (A
and C) or Fe(NO3)3 (B and D) as the sole iron source. MCV515 and MCV516 serve as the
positive and negative control strains, respectively.
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data not shown). To date, we have screened more than 14,000 mutants using this form of
mutagenesis and screening.
B. Identification of the transposon insertion sites
The ability of N. gonorrhoeae to utilize transferrin as an iron source is dependent on the
transferrin iron acquisition system described earlier. This system includes two outer membrane
proteins, TbpA and TbpB, and an energy transduction system, TonB-ExbB-ExbD. Thus,
disruption of their function could account for the Tf-negative and Fe(NO3)3–positive growth
phenotype. To ensure that the transposon insertion was not affecting their expression, we used
western blot analysis to examine the protein expression of TbpA, TbpB, and TonB in the
potential TbpB export mutants. Mutant 4912 showed wild-type expression of all three proteins
(Figure 6), indicating that these proteins were not affected by the mutation. We then used
ligation-mediated PCR (LMPCR) to amplify the gonococcal chromosomal DNA flanking the
transposon insertion. The PCR product was cloned into a TOPO vector and sequenced to
determine the location of the insert in the genome. The transposon in mutant 4912 mapped to
gene NG2117, a possible membrane-spanning domain (MSD) protein in an ABC transport
system. This is promising since an ABC transport system is an important part of the Lol system
in E. coli.
Mutants 11579 (data not shown) and 13614 (Figure 7) exhibited similar protein
expression profiles with wild-type expression levels and protein sizes for TbpA and TbpB.
However, detection of TonB in these mutants showed a protein with a higher molecular weight
and slightly lower level of expression than wild-type. This indicates that the transposon
insertions in mutants 11579 and 13614 were affecting the expression, and most likely, function
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Figure 6. Protein Expression of Tbps and TonB in mutant 4912. Whole cell lysates of ironstressed gonococci were subjected to SDS-PAGE and transferred to nitrocellulose. Blots were
probed with anti-TbpA (top panel), anti-TbpB (middle panel), or anti-TonB (bottom panel)
polyclonal antibodies. FA19 and MCV515 serve as the wild-type and parent strain controls,
respectively. FA6747 is a TbpA- control, FA6905 is a TbpB- control, and MCV650 is a TonBcontrol.
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Figure 7. Protein Expression of Tbps and TonB in mutant 13614. Whole cell lysates of
iron-stressed gonococci were subjected to SDS-PAGE and transferred to nitrocellulose. Blots
were probed with anti-TbpA (top panel), anti-TbpB (middle panel), or anti-TonB (bottom panel)
polyclonal antibodies. FA19 and MCV515 serve as the wild-type and parent strain controls,
respectively. FA6747 is a TbpA- control, FA6905 is a TbpB- control, and MCV650 is a TonBcontrol.
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of the TonB protein and/or TonB-ExbB-ExbD complex. LMPCR and DNA sequencing revealed
that the transposon inserted into the ExbD protein. Therefore, the insertion was affecting the
proper function of the TonB-ExbB-ExbD complex and this, rather than a TbpB export defect, is
responsible for the growth phenotype seen in these mutants.
C. Characterization of the surface exposure of TbpB in Mutant 4912
If lipoprotein export to the outer membrane or translocation to the outer leaflet was being
disrupted through the insertion of a transposon, then TbpB would remain either in the inner
membrane or in the inner leaflet of the outer membrane. Therefore, the surface accessibility of
TbpB would be affected and we would not be able to detect TbpB on the cell surface. We used
two different methods to determine surface exposure of the protein: protease accessibility and
whole-cell binding assays. It has been previously shown that surface exposed TbpB is
susceptible to trypsin degradation (51) and periplasmic TbpB is not susceptible to degradation
(unpublished data). We treated whole cells with trypsin for various lengths of time and detected
TbpB protein products through western blot analysis using anti-TbpB antibody (Figure 8). TbpB
detection showed susceptibility to trypsin digestion, demonstrating a protein banding pattern
similar to the wild-type strain (Figure 8). This degradation suggests that TbpB in mutant 4912 is
accessible on the cell surface and still getting exported to the outer membrane and oriented to
extracellular surface in mutant 4912
D. Mutant 4912 is a mixed population
After determining that mutant 4912 produces surface exposed TbpB, we retested the
growth phenotype on CDM plates. Samples of mutant 4912 displayed multiple growth
phenotypes with growth on transferrin but not Fe(NO3)3, no growth on either transferrin or
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Figure 8. Protease accessibility of TbpB in Mutant 4912. Iron-stressed gonococci were
treated with trypsin for 0, 15, and 30 minutes, followed by the addition of aprotinin. Whole cell
lysates were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with polyclonal
anti-TbpB serum. Untreated samples are labeled with U and treated samples are labeled with
their respective times. Arrows indicate trypsin-degraded products and molecular weight markers
are indicated on the right with strain names listed above. FA19 and MCV515 serve as the wildtype and parental controls, respectively.
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Fe(NO3)3, and growth on both transferrin and Fe(NO3)3 plates (Figure 9). None of the samples
exhibited the expected phenotype for a TbpB export deficient mutant in this screen. This
inconsistent growth phenotype indicated the original mutant that was thought to be colony
purified was actually a mixed population with different genotypes. A sample of mutant 4912
that demonstrated the original growth phenotype could not be isolated from the samples.
Therefore, no conclusions can be made about the involvement of the NG2117 gene in the
transport of TbpB and other lipoproteins to the outer membrane.

III. Discussion
In addition to acting as a selective barrier, the outer membrane holds many proteins that
serve a diverse array of functions, including nutrient uptake, enzymatic activities, and adhesion
and invasion. These proteins are essential for survival and localization to the correct
compartment of the cell envelope is necessary for their proper function. Although the Lol
system is well conserved among Gram-negative bacteria, differences in the protein apparatus and
signal sequences do exist (143). No functional Lol system or any other lipoprotein transport
system has been identified in N. gonorrhoeae. Additionally, gonococci produce surface exposed
lipoproteins, such as TbpB, that are anchored in the outer leaflet of the outer membrane, unlike
E. coli. However, no system of lipoprotein transport across the outer membrane has been
elucidated in N. gonorrhoeae or any other bacteria. We sought to identify the mechanism of
lipoprotein export to the outer membrane and orientation in the outer leaflet by exploiting the
transferrin-iron acquisition system N. gonorrhoeae.
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Figure 9. Growth phenotype of mutant 4912 is inconsistent. Multiple samples of potential
TbpB export deficient mutant 4912 were plated on CDM medium with either 30% saturated Tf
or Fe(NO3)3 as the sole iron source. All samples are individual isolates of mutant 4912 and
labeled with numbers 1 through 8. MCV515 and MCV516 serve as the positive and negative
control strains, respectively.
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To accomplish this, we used a transposon library, generated by the laboratory of William
Shafer at Emory University, to generate mutants in the gonococcal strain MCV515. This
background is completely dependent on the presence of TbpB at the cell surface to utilize
transferrin as an iron source. Therefore, if TbpB export to the cell surface is being interrupted by
the transposon insertion, the gonococci will not be able to grow on CDM-transferrin plates,
which serves as the screen when looking for potential mutants. This mutagenesis and screening
process appeared promising since the library had been previously used to identify important
genes involved in serum resistance (11) and the screen seemed straigTforward.
Using this method, we isolated three promising mutants that were unable to utilize
transferrin as an iron source (Figure 5). We performed western blot analysis of TbpA, TbpB,
and TonB to ensure that none of the major proteins involved in the uptake of iron from
transferrin were affected by the transposon insertion. Unfortunately, two of these, mutants
11579 and 13614, had altered TonB protein size and expression (Figure 7) caused by transposon
insertion in the ExbD gene. The ExbD protein is part of the TonB-ExbB-ExbD energy
transduction system necessary for TonB dependent transport. It had been shown previously that
the utilization of iron bound to transferrin, lactoferrin, and hemoglobin in Neisseria is dependent
on the TonB system (15, 194). Since the internalization of iron through the gonococcal
transferrin receptors is TonB dependent, the transposon insertion in ExbD and disruption of this
system is responsible for the growth phenotype. Therefore, the transport of TbpB to the cell
surface is not being affected in these mutants. However, this information is vital to our study
since it proves that the method of mutagenesis and screening can successfully identify
gonococcal isolates that are incapable of using transferrin as an iron source. These data also
suggest that ExbD, and possibly ExbB, has a significant role in the processing and expression of
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TonB. To our knowledge, this is the first data to show a role of ExbD in the protein expression
on TonB in Neisseria.
The other mutant obtained through this mutagenesis and screening process, mutant 4912,
had wild-type expression of the TbpA, TbpB, and TonB proteins (Figure 6), indicating that none
of these proteins were affected by the transposon insertion. Therefore, the growth phenotype
was due to the disruption of an undetermined gene which, though LMPCR and DNA sequencing,
was identified as gene NG2117. This gene encodes a possible membrane-spanning domain
protein in an ABC transport system. In the E. coli Lol system, LolC and LolE act as the
membrane spanning domains of the ABC transport with LolD acting as the ATP-binding domain
(204, 205). It is very likely that the neisserial lipoprotein transport system has a similar structure
and organization. Based on this, the NG2117 gene looked very promising as a component of the
lipoprotein transport machinery in Neisseria.
However, protease accessibility assays showed that TbpB was surface accessible and
present at the cell surface in mutant 4912 (Figure 8). These data imply that TbpB is surface
exposed and the export of lipoproteins to the outer leaflet of the outer membrane is functional.
Therefore, the ABC transport system MSD encoded by gene NG2117 may not be involved in the
transport of TbpB to the cell surface. Upon reexamination of the mutant’s growth phenotype, we
found that ability to utilize transferrin and Fe(NO3)3 as iron sources varied with different samples
(Figure 9), indicating that mutant 4912 is a mixed population. This denotes that various
genotypes are present in the mutant 4912 population, which includes other mutations in addition
to the NG2117 mutation. Therefore, the samples used for the protease accessibility assay
contained multiple genotypes and phenotypes. This confounds the results of this assay since a
TbpB export deficient phenotype may be obscured by the presence of gonococci that are capable
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of TbpB export. An isogenic population is needed for the evaluation of NG2117 participation in
TbpB localization. Thus, no conclusions can be made about the possible function of NG2117 in
the transport of lipoproteins to the outer membrane.
To date, we have screened over 14,000 mutants using the transposon library and
transferrin utilization screening method. With the number of mutants screened and the size of
the transposon library, it seems that we have exhausted this approach of identifying the export
mechanism of lipoproteins in N. gonorrhoeae. Additionally, we have isolated duplicates of
mutants, further confirming that we have reached the system’s capacity. Two rationales exist as
to the failure of this method. First, since the transposon library was made from a collection of
10,000 colonies, it is limited in the number of mutations it contains and the mutations we were
screening for may not be included. Second, disruption of the lipoprotein export system may be
lethal in the gonococci and deletions of the proteins involved cannot be obtained. This is a
possibility since all of the Lol proteins in E. coli are essential for growth (142, 199, 200). The
transport mechanisms of neisserial lipoproteins to the outer membrane and orientation to the cell
surface remain unknown.
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Chapter 4: Characterization of C-lobe Deletion of TbpB

I. Introduction
Iron is an essential nutrient for most organisms and is required for bacterial growth.
Therefore, most pathogens have evolved several mechanisms of obtaining iron in the human
host, which is seen as a virulence factor. One method is the utilization of host iron-binding
proteins, such as transferrin, through bacterial receptor-mediated interactions. Members of the
Neisseriaceae, Pastuerellaceae, and Moraxellaceae families are capable of using transferrin as
an iron source and their transferrin iron acquisition systems have been studied extensively. The
transferrin receptor complex is vital for bacterial infection of the natural host (10, 50), indicating
the importance of transferrin iron acquisition.
These transferrin iron uptake systems consist of two distinct outer membrane proteins:
transferrin binding protein (Tbp) A and B. Both proteins specifically and independently bind
transferrin but only TbpA is necessary for the use of transferrin-bound iron (51). TbpA is a
TonB-dependent transporter that is responsible for translocating iron across the outer membrane,
into the cell (49). TbpB is a bilobed, surface exposed lipoprotein whose precise role in the
utilization of transferrin as an iron source has not yet been defined. However, it makes the
internalization of transferrin-bound iron more efficient by distinguishing between apo- and holotransferrin (26, 51). This enhances the interaction between the transferrin receptor complex and
the ferrated transferrin molecule, which is the optimum ligand for the iron transport system.
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Transferrin is a monomeric, serum glycoprotein that binds iron for sequestering and
transport. It has two homologous domains, the N-lobe and C-lobe, each containing an ironbinding site (117). This bilobed structure resulted from an early gene duplication with
independent evolution of the two domains subsequently (233). Although iron preferentially
binds the N-lobe (235), it has been demonstrated that only the C-lobe of human transferrin is
capable of binding to the Tbps (3, 163). The crystal structure of the meningococcal Tbps in
complex with iron-bound human transferrin also showed both Tbps interacting tightly with the
C-lobe, having unique, non-overlapping binding sites (146). However, the C-lobe alone was
unable to support the growth of iron-limited cultures of N. meningitidis, suggesting that both
lobes are necessary for efficient iron release from transferrin (2).
It has long been hypothesized that TbpB is bilobed, similar to transferrin, based on
internal sequence redundancy (125) and regions of identity between the N-terminal and Cterminal halves (164). These conserved regions of TbpB are interspersed within hypervariable
domains (167) and are also observed in other species, such as M. catarrhalis, H. influenzae,
Pasteurella haemolytica, and Actinobacillus pleuropneumoniae (164). The bilobed structure of
TbpB was recently confirmed by the crystal structure of the protein from both A.
pleuropneumoniae (132) and N. meningitidis (32, 146). The crystal structures also revealed the
structural similarity between the lobes with each lobe subdivided into an eight-strand -barrel
domain and an adjacent four-strand handle domain (32, 132, 146). Due to the similar bilobed
structure of transferrin and TbpB, it has been hypothesized that TbpB evolved in parallel with
transferrin to adapt to its ligand (125).
The contribution of the two lobes to the function of TbpB has been well studied but
remains controversial. In N. meningitidis, both lobes have been attributed with transferrin
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binding. Although initial studies showed only the N-lobe is involved in transferrin binding
(213), subsequent studies have also implicated the C-lobe (162, 164). These studies
demonstrated that both the N-terminal and C-terminal halves of TbpB could bind independently
to human transferrin, but the N-lobe binds with higher affinity than the C-lobe (162, 164). It has
been speculated that the transferrin and TbpB interaction occurs primarily between the Tf C-lobe
and TbpB N-lobe but an additional low-affinity interaction may also occur between the Tf Nlobe and TbpB C-lobe (162, 164). However, all of these studies used recombinant TbpB proteins
with many of them using purified fusion proteins.
Cornelissen et al. used the ability of TbpB to bind transferrin on a ligand-binding western
blot to define a minimal domain necessary for transferrin binding by gonococcal TbpB (47).
They made progressive deletions from the C-terminal end of TbpB and cloned them into E. coli
to analyze the role of several conserved regions in transferrin binding. All of the deletion
constructs were expressed by E. coli but only a deletion from the N-terminal and the largest Cterminal deletion, which included a conserved region in the end of the N-terminal half, were
unable to bind transferrin. These results suggested that only the conserved regions in the Nterminal half of TbpB are involved in transferrin binding. Again, this study used recombinant
proteins, providing insight into in vitro transferrin binding of TbpB.
However, in vivo studies by DeRocco and Cornelissen using intact gonococcal cells
demonstrated that both the N- and C-lobes were involved in transferrin binding at the cell surface
and utilization of transferrin as an iron source (57). Hemagglutinin (HA) epitopes were inserted
into 9 locations within TbpB, 5 in the N-lobe and 4 in the C-lobe. Through ligand-binding
western blot analysis, they demonstrated that only HA insertions 3, 4, and 5, which were all
located within the N-lobe, diminished transferrin binding, consistent with the previous study.
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However, whole-cell binding assays revealed that HA insertions 4 and 5, as well as 8, decrease
transferrin binding at the gonococcal cell surface. HA8 insertion is in the C-lobe and in
combination with either HA4 or HA5 insertions, transferrin binding was completely abolished at
the cell surface. Transferrin utilization and iron internalization was also impaired in these three
individual HA insertions, determined by growth assays on CDM-transferrin and iron uptake
assays using radiolabeled iron, respectively. Taken together, these data suggest that although
only the N-lobe is required for in vitro transferrin binding using isolated protein, both lobes are
involved in transferrin binding and utilization in whole, intact gonococcal cells, referred to as in
vivo in this study.
To further delineate the role of the C-lobe in transferrin binding and iron stripping, we
generated a C-lobe deletion mutant of TbpB through DNA splicing by directed ligation (107).
This mutant included the full length, wild-type N-lobe and the linker region connecting the two
lobes. We used this mutant to characterize the expression of the single TbpB lobe in both N.
gonorrhoeae and E. coli. We also analyzed the ability of the N-lobe alone to bind transferrin by
ligand-binding western blot analysis and on the cell surface through whole-cell binding assays.
Finally, we evaluated transferrin utilization in the mutant by plating it on CDM-transferrin
medium. Since previous studies in both N. meningitidis and N. gonorrhoeae demonstrated that
in vitro transferrin binding occurs primarily in the N-lobe, we hypothesized the TbpB C-lobe
deletion protein would still be able to bind transferrin by ligand-binding western blot. However,
we hypothesized that deletion of the C-lobe would hinder the function of TbpB in the
gonococcus since both lobes were shown to be involved in transferrin binding and utilization at
the cell surface (57).
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II. Results
A. Deletion of the C-lobe causes degradation of TbpB
Based on the TbpB gonococcal sequence and gonococcal homology model of the
meningococcal TbpB crystal structure (146), we constructed a full and precise deletion of the Clobe of gonococcal TbpB. The deletion gene was designed to end at the exact beginning of the
C-lobe so it included the full N-lobe as well as the full linker region connecting the lobes. The
C-lobe deletion gene was transformed into wild-type (FA19), insertional inactivated TbpA
(FA6747), and TbpB-dependent for Tf utilization (MCV515) gonococcal background strains to
be characterized. Expression of the TbpB C-lobe deletion protein was examined using western
blot analysis, probing with anti-TbpB antibody. These gonococcal liquid cultures grown under
iron-stressed conditions for 4 hours expressed no detectable TbpB C-lobe deletion protein
(Figure 10). Additionally, no TbpB protein was detected in strains grown on GCB supplemented
with DFO plates to induce iron-stressed conditions (Figure 11). However, breakdown products
of TbpB were able to be detected indicating that some protein was being produced. Most of the
antibody reactive material in the C-lobe deletion strains was located at the bottom of the blot as
degraded product. This suggested that the TbpB C-lobe deletion protein was being produced but
degraded in N. gonorrhoeae.
Since the previous work to identify the regions of gonococcal TbpB involved in
transferrin binding was done using recombinant proteins epressed in E. coli, we cloned the same
tbpB sequence from the C-lobe deletion gene into pET-22b(+) expression vector and transformed
it into BL21(pLysS) E. coli cells. Similar to the constructs made by Cornelissen et al., this
cloned gene did not contain the native promoter or lipidation signal. Protein expression of the C-
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Figure 10. Degradation of TbpB in gonococcal C-lobe deletion strains grown in liquid
cultures. Whole cell lysates of iron-stressed gonococci grown in liquid culture for 4 hours were
subjected to SDS-PAGE and transferred to nitrocellulose. Blots were probed with anti-TbpB
polyclonal antibody. FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent
strain controls. Deletion of the TbpB C-lobe in these backgrounds is indicated with C.
FA6815 and FA6819 serve as controls for deletions in the tbpB gene. Molecular weight markers
are indicated on the right.
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Figure 11. Degradation of TbpB in gonococcal C-lobe deletion strains grown on plates.
Whole cell lysates of iron-stressed gonococci grown on GCB agar plates with DFO were
subjected to SDS-PAGE and transferred to nitrocellulose. Blots were probed with anti-TbpB
polyclonal antibody. FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent
strain controls. Deletion of the TbpB C-lobe in these backgrounds is indicated with C.
FA6815 and FA6819 serve as controls for deletions in the tbpB gene. Molecular weight markers
are indicated on the right.
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lobe deletion in E. coli was induced using IPTG and whole cell lysates taken at one-hour
timepoints were analyzed by western blot analysis, probing with anti-TbpB antibodies.
Interestingly, the TbpB C-lobe deletion protein was detected in E. coli at the expected molecular
weight (Figure 12). However, the protein was detected at a very low expression level only at the
one hour induced timepoint (Figure 12). The protein band disappeared after two and three hours
of induction (Figure 12), indicating that the protein is also being degraded in E. coli. The
previously made constructs were expressed at normal detectable levels in E. coli, suggesting that
something specific about this C-lobe deletion construct caused the protein to be degraded.
After detection at the one hour timepoint in E. coli, we grew iron-stressed cultures of the
C-lobe deletion gonococcal strain in the wild-type FA19 background taking one-hour timepoints.
We again analyzed the protein expression of the C-lobe deletion of TbpB by western blot
analysis but used a more sensitive anti-TbpB antibody. With this, we were able to detect a band
that increased over time with the increase of iron starvation around the same molecular weight as
the C-lobe deletion in E. coli (Figure 13). We judged this to be the TbpB C-lobe deletion protein
in N. gonorrhoeae which was detectable with the more sensitive antibody but still expressed at a
much lower level than wild-type TbpB. This further implies that the C-lobe deletion protein of
TbpB is being degraded.
B. TbpB N-lobe is unable to bind transferrin in vitro and in vivo
The ability of TbpB to bind transferrin is retained after denaturation and SDS-PAGE
analysis, and HRP-transferrin can be used to detect transferrin binding on a ligand-binding
western blot. We used this characteristic to determine the transferrin binding capability of the
TbpB N-lobe protein that was made by the deletion of the C-lobe in N. gonorrhoeae. The
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Figure 12. Degradation of induced TbpB N-lobe construct in E. coli. Whole cell lysates
were taken at one-hour timepoints of IPTG-induced E. coli containing the TbpB N-lobe construct
in pET-22b(+) expression vector. Lysates were subjected to SDS-PAGE, transferred to
nitrocellulose, and probed with anti-TbpB polyclonal antibody. Samples of the induction of
TbpB N-lobe construct in E. coli are indicated by their timepoints. FA19 and FA19 C are the
TbpB wild-type and C-lobe deletion gonococcal control strains, respectively. FA6819 serves as
a control for deletions in the gonococcal tbpB gene and pUNCH750 serves as a control for the
expression of tbpB gene deletions in an expression vector in E. coli. Molecular weight markers
are indicated on the right and the arrow indicates the TbpB C-lobe deletion.
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Figure 13. Detection of gonococcal TbpB C-lobe deletion over time. The TbpB C-lobe
deletion gonococcal strain (FA19 C) was grown under iron-stressed conditions in liquid
cultures. Whole cell lysates of the TbpB C-lobe deletion gonococci were taken every hour for 4
hours. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with antiTbpB polyclonal antibody. Samples of FA19 C are indicated by their respective timepoints.
FA19 serves as the wild-type TbpB and parent strain control. E. coli N-lobe serves as the TbpB
C-lobe deletion control for size comparison and pUNCH750 serves as a control for the
expression of tbpB gene deletions in an expression vector in E. coli. Molecular weight markers
are indicated on the right and the arrow indicates the TbpB C-lobe deletion.
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western blot detecting Tf binding revealed that the N-lobe alone was incapable of binding
transferrin in any gonococcal background (Figure 14). Western blot analysis of the one hour
timepoints of the TbpB C-lobe deletion in wild-type FA19 background also showed that the Nlobe protein was not able to bind transferrin at any time of iron-stress (Figure 15A). A longer
exposure revealed that the protein might be capable of minimal transferrin binding (Figure 15B).
However, these data suggested that deletion of the C-lobe renders the remaining N-lobe TbpB
protein unable to bind transferrin at detectable levels in vitro and nonfunctional in the
gonococcus.
The transferrin binding capability of the gonococcal TbpB C-lobe deletion protein
created in this study was also examined in E. coli strain containing the C-lobe deletion construct.
To do so, whole cell lysate of the one hour induced sample was run on an SDS-PAGE gel in
parallel with previously made TbpB constructs (pUNCH plasmids; Table 1) generated by James
E. Anderson from the Cornelissen et al. studies identifying the minimal transferrin binding
domain of TbpB (47). They used intrinsic restriction enzyme sites in the gonococcal tbpB
sequence to make progressive deletions of from the C-terminal end. These constructs do not
contain the native promoter or N-terminal signal sequence and vary in their ability to bind
transferrin. We again used anti-TbpB antibody to detect the expression of the TbpB constructs
and HRP-transferrin to analyze their transferrin binding capabilities. TbpB expression was
detected in all of the whole cell lysates (Figure 16A) with transferrin binding only eliminated in
the pUNCH770 plasmid and C-lobe deletion protein (Figure 16B). This further implies that the
TbpB C-lobe deletion protein is unable to bind transferrin in vitro.
In addition, we evaluated the ability of the TbpB C-lobe deletion protein to bind
transferrin at the cell surface by whole-cell binding assays. This was done in a TbpA inactivated
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Figure 14. TbpB C-lobe deletion is unable to bind transferrin in gonococcal strains. Whole
cell lysates of iron-stressed gonococci grown in liquid culture for 4 hours were subjected to SDSPAGE and transferred to nitrocellulose. Blots were probed with HRP-Tf to detect transferrin
binding by TbpB. FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent strain
controls. Deletion of the TbpB C-lobe in these backgrounds is indicated with C. FA6815 and
FA6819 serve as transferrin binding negative controls of gonococcal strains containing tbpB
gene deletions. Molecular weight markers are indicated on the right.
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Figure 15. Detection of transferrin binding by gonococcal TbpB C-lobe deletion over time.
The TbpB C-lobe deletion gonococcal strain (FA19 C) was grown under iron-stressed
conditions in liquid cultures. Whole cell lysates of the TbpB C-lobe deletion gonococci were
taken every hour for 4 hours. Lysates were subjected to SDS-PAGE, transferred to
nitrocellulose, and probed with HRP-Tf to detect transferrin binding with short (A) and long (B)
exposures to film. Samples of FA19 C are indicated by their respective timepoints. FA19
serves as the wild-type TbpB and parent strain control. E. coli N-lobe serves as the TbpB C-lobe
deletion control for size comparison and transferrin binding negative control. pUNCH750 serves
as a positive control for transferrin binding of a tbpB gene deletion in E. coli. Molecular weight
markers are indicated on the right and the arrow indicates the TbpB C-lobe deletion.
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Figure 16. TbpB C-lobe deletion is unable to bind transferrin in E. coli strains. Whole cell
lysates of IPTG-induced E. coli containing plasmids with different C-terminal deletions of
gonococcal TbpB were subjected to SDS-PAGE and transferred to nitrocellulose. Blots were
probed with polyclonal anti-TbpB serum (A) and HRP-Tf to detect transferrin binding by TbpB
(B). The previously made pUNCH plasmids (Table 1) are labeled with their respective numbers.
pUNCH750, 768, 769, and 772 are positive transferrin binding E. coli controls. pUNCH 770 is
the negative transferrin binding E. coli strain. The E. coli TbpB C-lobe deletion constructed in
the current study is labeled E. coli N-lobe. FA19 serves as the wild-type TbpB in a gonococcal
backrgound. FA6819 serves as a transferrin binding negative control of gonococcal strains
containing tbpB gene deletions. Molecular weight markers are indicated on the right and the
arrow indicates the TbpB C-lobe deletion.
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background, FA6747, since both Tbps are independently capable of binding transferrin. To
ensure that the TbpB protein was being produced at a detectable level in the FA6747 C-lobe
deletion strain, we used anti-TbpB antibody to detect protein expression. However, this does not
provide any information on the cellular localization of TbpB or structural integrity of the protein
since periplasmic TbpB as well as fragments of TbpB are able to be detected in this assay. TbpB
protein expression was able to be detected in the FA6747 TbpB C-lobe deletion strain (Figure
17A). However, transferrin binding was not detected in this strain with HRP-transferrin (Figure
17B), indicating that either the protein being made is unable to bind transferrin or that there is
not enough protein present on the cell surface, due to degradation, to detect transferrin binding.
Expression of TbpB and transferrin binding were also analyzed using whole-cell binding assays
at one hour timepoints taken when growing the cultures under iron-stressed conditions.
Although an increase of TbpB expression was seen with increasing time and iron-stress (Figure
18A), no transferrin binding was able to be detected at any of the timepoints (Figure 18B).
These data suggested that the C-lobe deletion strain is unable to bind transferrin in vivo at the
gonococcal cell surface.
C. Utilization of transferrin is impaired in the TbpB C-lobe deletion
To analyze the impact of the TbpB C-lobe deletion on the function of the transferrin iron
acquisition system, we again used the gonococcal strain MCV515 which has a mutation in TbpA
that makes it completely dependent on TbpB for the use of transferrin as an iron source. We
combined the TbpA mutation with the TbpB C-lobe deletion to determine if the deletion of the
C-lobe impairs the function of TbpB based on its ability to compensate for the TbpA defect. We
examined the growth phenotype of the MCV515 TbpB C-lobe deletion strain on CDM-
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Figure 17. Whole-cell binding assays of TbpB C-lobe deletion strains. Iron stressed whole
gonococci were applied to nitrocellulose and probed with polyclonal anti-TbpB serum (A).
Surface transferrin binding was examined by probing with HRP-Tf (B). Each lane is labeled
according to strain name. FA6905 serves as TbpB-negative and Tf binding-positive control and
FA6815 serves as a TbpB-positive and Tf binding-negative control. FA19 and FA6747 are the
parental strains for the TbpB C-lobe deletion in these backgrounds, indicated by C.
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Figure 18. Whole-cell binding assays of TbpB C-lobe deletion strains over time. Iron
stressed whole gonococci were applied to nitrocellulose and probed with polyclonal anti-TbpB
serum (A). Surface transferrin binding was examined by probing with HRP-Tf (B). Each lane is
labeled according to strain name. FA6905 serves as TbpB-negative and Tf binding-positive
control and FA6815 serves as a TbpB-positive and Tf binding-negative control. FA19 and
FA6747 are the parental strains for the TbpB C-lobe deletion in these backgrounds, indicated by
C. Samples of FA6747C were taken every hour for 4 hours, indicated by their respective
time, to detect changes in TbpB expression and Tf binding over time.
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transferrin and found that transferrin utilization was reduced, compared to the parental MCV515
strain (Figure 19). However, growth was not completely abolished in the C-lobe deletion strain,
as seen in the negative control MCV516 which is the parental strain with the deletion of TbpB
(Figure 19). This indicates that some function of TbpB is retained in the C-lobe deletion protein.
To further characterize the growth phenotype, the MCV515 TbpB C-lobe deletion strain
was plated on CDM containing different percent saturated transferrin in parallel with the HA
epitope insertions 4, 5, and 8 in the same background. The saturation percentages of transferrin
used were 5, 10, 20, 30, and 50. The three HA epitope insertions and the TbpB C-lobe deletion
showed diminished growth compared to the parent strain on all plates, even the 50% saturated
transferrin (Figure 20). However, none of them exhibited the same phenotype as the negative
control, MCV516, which was unable to grow at all (Figure 20). Therefore, although all of these
mutations impaired the function of TbpB, none of them abolished its function in compensating
for the TbpA defect. Interestingly, the TbpB C-lobe deletion strain behaved most like the HA4
N-lobe insertion rather than the HA8 C-lobe insertion (Figure 20). This indicated that deletion of
the TbpB C-lobe caused a more significant effect on TbpB function compared to disruption of
the C-lobe lobe by an insertion, further confirming the role of the C-lobe in the proper function
of TbpB. Despite the fact that the TbpB C-lobe deletion protein is unable to bind transferrin by
western blot and whole-cell binding assays, some of its role in transferrin utilization is retained.

III. Discussion
The recent crystal structure of meningococcal TbpB confirmed the bilobed structure of
the protein. However, the involvement of the individual lobes in the function of neisserial TbpB
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Figure 19. TbpB C-lobe deletion is able to support limited growth. Samples of the TbpB Clobe deletion in the MCV515 gonococcal background were plated onto CDM medium containing
30% saturated Tf as the sole iron source. MCV515 and MCV516 serve as the positive and
negative control strains, respectively. MCV833 serves as a control for a C-lobe TbpB mutation
that affects transferrin binding and utilization.
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Figure 20. TbpB C-lobe deletion behaves similarly to the TbpB HA epitope insertions.
Samples of the TbpB C-lobe deletion in the MCV515 gonococcal background were plated in
parallel with the TbpB HA epitope insertion mutants in the same background onto CDM medium
containing different levels of saturation of Tf. Saturation percentages used were 5 (A), 10 (B),
20 (C), 30 (D), and 50 (E). MCV515 and MCV516 serve as the positive and negative control
strains, respectively. MCV829 and MCV830 have HA epitope insertions in the TbpB N-lobe
and MCV833 has an HA epitope insertion in the TbpB C-lobe, all of which affect transferrin
binding and utilization.

97

A.

MCV515

B.

MCV516

MCV516

MCV515
C

MCV515
C

MCV
829

MCV
829

MCV833
C.

MCV515

MCV830
D.

MCV516

MCV515

MCV833

MCV830

MCV516

MCV515

MCV515
C

MCV515
C

MCV
829

MCV
829

MCV833

MCV830
E.

MCV515

MCV515
C

MCV833

MCV833

MCV830

MCV516

MCV829

MCV830

98
is still debated. Previous in vitro studies using gonococcal TbpB showed that only regions in the
N-lobe are responsible for high affinity transferrin binding (47) while in vivo studies
demonstrated that both lobes are necessary for function of TbpB in the native gonococcus (57).
The purpose of this study was to determine the role of the C-lobe in the transferrin iron
acquisition function of gonococcal TbpB. To accomplish this, a precise, full deletion of the Clobe of TbpB was constructed and characterized. Western blot analysis indicated that deletion of
the C-lobe causes degradation of the TbpB protein in both gonococci (Figures 10, 11, and 13)
and E. coli (Figure 12). It also revealed that the minimal N-lobe TbpB protein not broken down
in these backgrounds is unable to bind transferrin (Figures 14, 15, and 16). Additionally, the Nlobe TbpB protein was incapable of binding transferrin at the cell surface in whole-cell binding
assays (Figures 17 and 18). When transferrin utilization was tested, the N-lobe was able to
support very limited growth on human transferrin as an iron source (Figures 19 and 20), which
was contradictory to the transferrin binding assays.
Deletion of the C-lobe of TbpB resulted in the degradation of the expressed protein,
which consists of the N-terminal half and linker region connecting the two lobes. Degradation
was seen with both liquid and plate cultures, indicating that this outcome is not affected by the
method of growth. This was surprising since previous deletion mutants FA6815 and FA6819
(5), which result in shorter peptides than the C-lobe deletion and incapable of binding transferrin,
are still expressed at wild-type levels. These results indicate that a specific characteristic of the
C-lobe deletion protein created in the current study causes it to be broken down. The
degradation of the protein in E. coli is also peculiar since previous C-terminal deletion mutants,
both longer and shorter, were properly expressed in this bacterium (47). Breakdown of the
protein in E. coli shows that degradation of the protein is not restricted to the native gonococcus,
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indicating a general reason common to both bacterial species. Furthermore, since the E. coli Clobe deletion construct does not contain the native gonococcal TbpB signal sequence, it remains
in the cytoplasm where it gets degraded. Although it is impossible to determine if the
gonococcal TbpB C-lobe deletion peptide is degraded in the cytoplasm or periplasm, it is likely
that the TbpB protein is also broken down in the cytoplasm of the gonococcus before it is able to
be transported across the inner membrane.
Degradation of the TbpB C-lobe deletion protein could occur through several different
methods. First, the structure of the full length N-lobe alone could be unstable causing limited or
improper folding of the protein which leads to the degradation of the protein. Additionally, the
presence of the linker region of the protein could be responsible for the degradation. The two
lobes of TbpB are connected by a short, unstructured linker region which was included in the
construct of the C-lobe deletion gene. With no fragment of the C-lobe to form some kind of
structural protection, the linker region would be exposed in the cellular environment. This could
increase the instability of the protein or be available for digestion by proteases, leading to the
degradation of the entire protein.
Although we hypothesized that the deletion of the C-lobe would only slightly affect
transferrin binding since the N-lobe remained intact, the N-lobe protein produced by the deletion
of the C-lobe was not able to bind transferrin on western blots in either a gonococcal or E. coli
background (Figures 14, 15, and 16). Although a longer exposure demonstrated some weak
transferrin binding, it was negligible compared to wild-type and may have been nonspecific. The
previously made TbpB constructs in E. coli showed that the only C-terminal deletion affecting
transferrin binding removed all of the C-terminal half as well as a portion of the N-terminal half
(47). The next smaller deletion included the beginning of the C-terminal half and transferrin
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binding was retained with this construct. Therefore, the C-lobe deletion of TbpB created in this
study is in between these two constructs and its transferrin binding capability could only be
postulated. The minimal expression of stable TbpB in the C-lobe deletion strains could account
for the absence of detectable transferrin binding. However, the detection of TbpB using HRPtransferrin is much more sensitive than the TbpB antibodies. If the protein was capable of
specific binding to transferrin, we should have been able to detect it on the western blot with
HRP-transferrin. Additionally, due to the instability of protein demonstrated by its degradation,
the structure of TbpB that is retained during denaturation and SDS-PAGE analysis could also
have been affected by the deletion of the C-lobe, diminishing its ability to bind transferrin on a
western blot even if it were capable. The western blot analyses examining the transferrin binding
of the TbpB C-lobe deletion protein revealed that the gonococcal TbpB N-lobe is incapable of in
vitro transferrin binding.
Transferrin binding by the TbpB C-lobe deletion protein at the cell surface was also not
detected in the whole-cell binding assays. The instability of the N-lobe portion of TbpB
resulting in the decreased expression of the protein could account for the inability of transferrin
binding to be detected. The whole-cell binding assay may also not be sensitive enough to detect
the diminished expression of TbpB on the cell surface, although previous studies have shown
that this assay is capable of detecting reduced transferrin binding by TbpB (5, 51, 57). Although
alternative explanations exist, these results demonstrate that the TbpB C-lobe deletion protein is
also unable to bind transferrin in vivo, and together with the in vitro binding data, suggest that
the gonococcal N-lobe construct generated in the current study is not capable of specific binding
transferrin independent from the C-lobe.
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A previous study examining the functional domains of TbpA involved in transferrin
binding and utilization demonstrated that in one TbpA mutant, wild-type TbpB provided a
compensatory function allowing the use of transferrin as an iron source (243). This TbpA
mutant was used to determine the effect of the C-lobe deletion in the function of TbpB in the
gonococcus. Since absolutely no transferrin binding by the protein at the cell surface was
detected, it was surprising to see that the TbpB C-lobe deletion protein could compensate for the
TbpA defect in background strain MCV515 strain and growth was still weakly sustained by
transferrin. One theory to explain this is that the whole-cell binding assay is not sensitive
enough to detect the little transferrin binding that occurs at the cell surface by the C-lobe deletion
protein. However, this small amount of transferrin binding by TbpB is able to support growth of
the gonococci, but at a reduced capacity. Additionally, this could be explained by an alternative
function of TbpB in the acquisition of iron from transferrin that is independent of TbpB’s ability
to bind transferrin. An interaction between TbpA and TbpB could be involved in the
internalization and utilization of transferrin-bound iron and this alternative function is retained in
the TbpB C-lobe deletion protein. Therefore, deletion of the C-lobe does not interrupt this
interaction and the N-lobe is able to compensate for the TbpA defect independently.
In summary, deletion of the C-lobe of TbpB caused degradation of the protein in a
bacterial species and cellular localization independent manner. No in vitro or in vivo transferrin
binding by the C-lobe deletion protein was detected under normal assay conditions. This
supports the importance of the C-lobe in TbpB’s function of binding to transferrin. Finally, the
C-lobe deletion protein supported limited growth of the gonococci on transferrin in a manner that
is independent of the transferrin binding function of the protein. Our results indicated that both
N- and C-terminal halves must be present to achieve wild-type function of the TbpB protein.
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CHAPTER 5: Summary

Neisseria gonorrhoeae is an obligate human pathogen and extremely well adapted to
survive in the human host. It is responsible for causing the sexually transmitted infection
gonorrhea, which is the second most commonly reported infectios disease in the United States
(37). The third generation cephalosporins are the only recommended treatment due to rise in
resistance to previously effective antibiotics but increases in cephalosporin resistance have been
reported (9, 38), with the first high level clinical resistance reported in early 2011 (147).
Treatment options are rapidly diminishing and vaccine development against N. gonorrhoeae has
been unsuccessful thus far. Therefore, the development of new preventative and therapeutic
methods is imperative. Transferrin binding proteins (Tbps) are appealing vaccine candidates
because they are surface exposed, not highly variable, expressed in all clinical isolates, and
necessary for the establishment of infection in human males (50, 130). TbpB, in particular, has a
more significant role in producing an antibody response in mouse immunizations with
gonococcal proteins (156) and in meningococcal infections (113, 151, 152, 168) as well as other
bacterial infections (139, 171, 222). Understanding TbpB structure and function within the
gonococcus is necessary for its potential use in the development of a treatment or vaccine.
The gonococcal transferrin receptor complex is composed of two outer membrane
proteins. TbpA is a TonB dependent outer membrane transporter and TbpB is the associated
lipoprotein. Although it is not essential for transferrin utilization, TbpB is able to distinguish
between free and iron-bound transferrin, increasing the efficiency of iron uptake (51). However,

103
its exact role in transferrin-iron internalization has not yet been fully determined. TbpB is fully
surface exposed and anchored in the outer leaflet of the outer membrane (57). The mechanism
of TbpB export to the outer membrane and localization to the outer leaflet has not yet been
identified. Internal homology and crystal structure studies of neisserial TbpB revealed the
bilobed structure of the protein. Although the N-lobe has been shown to be involved in
transferrin binding, the role of the C-lobe has been debated and remains controversial (47, 57,
162, 164, 213).
The overall goals of this study were to identify the transport mechanism of TbpB to the
outer membrane and further delineate the role of the C-lobe of TbpB in transferrin binding and
utilization. Since the process of TbpB export is unknown, isolating and characterizing the
factors involved in the transport of TbpB could present new therapeutic targets. Structurefunction analyses of TbpB would provide valuable insight into its role in the transferrin iron
acquisition system and could lead to the development of new therapeutic agents. Both objectives
can lead to a better understanding of the pathogenesis of the microorganism.
Lipoprotein export in E. coli is accomplished through the function of the Lol system
which is well conserved among Gram-negative bacteria. However, neisserial lipoproteins do not
seem to be transported through the Lol system, indicating the presence of Lol-independent
transport machinery (214). Additionally, unlike E. coli, Neisseria produce lipoproteins that are
surface exposed and anchored in the outer leaflet of the outer membrane. The protein(s)
involved in the translocation of lipoproteins across the outer membrane have also not yet been
identified. We sought to characterize the gonococcal lipoprotein transport machinery through
mutagenesis using a transposon library. We were able to isolate three potential TbpB export
deficient mutants but only one, mutant 4912, showed promise after classification of the
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transposon insertion site. The disrupted gene, NG2117, encodes a possible MSD protein in an
ABC transport system, which is an integral component of an ABC transporter. Since an ABC
transporter is part of the Lol system and is most likely required for lipoprotein detachment from
the inner membrane, NG2117 could be involved in lipoprotein export in N. gonorrhoeae.
Our protease accessibility assays revealed surface exposure of TbpB in this mutant, and
reexamination of mutant 4912 samples revealed multiple genotypes within the population.
Therefore, no conclusions can be drawn from the data presented in the current study since the
samples were a mixed population with different lipoprotein export phenotypes. Further studies
are needed to isolate an isogenic population of the NG2117 mutant or create a deletion of the
NG2117 protein and characterize the surface exposure of TbpB in that mutant. Although
conclusions could not be made, our data identified a protein that has the potential to be involved
in gonococcal lipoprotein export.
Using the transposon library, we have screened over 14,000 mutants and have likely
exhausted this method of finding the TbpB export system, due to either the limitation of the
library or potential lethal nature of interrupting the lipoprotein transport process. Since deletion
of the Lol proteins in E. coli is lethal (142, 199, 200), disruption of the lipoprotein transport
system in N. gonorrhoeae may also be lethal. Blocking the transport of TbpB and other
lipoproteins could provide potential therapeutic effects. Therefore, identifying the mechanism of
transport of TbpB to the outer leaflet of the outer membrane could present new treatment and
vaccine targets.
Previous in vitro studies using recombinant proteins and western blot analysis that
defined a minimal domain necessary for transferrin binding determined that only conserved
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regions in the N-terminal half of gonococcal TbpB were involved in high affinity transferrin
binding (47). Conversely, studies using whole, intact gonococcal cells demonstrated a role of the
C-lobe in binding and utilization of transferrin in vivo at the cell surface (57). We sought to
further delineate the role of the C-lobe in gonococcal TbpB function by constructing and
characterizing a full, precise C-lobe deletion, both in vitro and in vivo. Based on the previous
studies, we hypothesized that deletion of the C-lobe would impair TbpB function but some
transferrin binding by the N-lobe would be retained.
However, we showed that deletion of the C-lobe of gonococcal TbpB results in the
degradation of the protein. Unfortunately, this degradation of the TbpB C-lobe deletion protein
obfuscates the transferrin binding ability of the N-lobe but our results indicate what little N-lobe
protein remains intact is not capable of binding transferrin. The method of degradation is
unknown and specific to this construct since other TbpB deletions are stably expressed. It seems
likely that the presence of the unstructured linker region is responsible for initiating breakdown
of the protein, and the absence of detectable transferrin binding is a result of this instability.
Interestingly, our studies also demonstrated that some function of TbpB is retained in the C-lobe
deletion protein when transferrin utilization is analyzed by cell growth, despite the lack of
detectable transferrin binding. This could be explained by the proper expression and export of a
minimal amount of TbpB C-lobe deletion protein that is still capable of binding tranferrin.
Additionally, an alternative function of TbpB, through an interaction with TbpA, may aid in the
use of transferrin-bound iron and is independent of its function in transferrin binding.
Overall, our studies on the deletion of the TbpB C-lobe indicated that both lobes of TbpB
contribute to the proper function of the protein, which may go beyond transferrin binding.
Identifying the functional domains of TbpB is essential in exploring their potential as therapeutic

106
targets and vaccine candidates. Price et al. demonstrated recombinant gonococcal Tbps
conjugated to cholera toxin B subunit are capable of inducing an antibody response in mice, and
TbpB generated a greater response than TbpA (156). The results presented here could have an
impact on development of TbpB-based vaccine against N. gonorrhoeae by providing insight into
the important structural features involved in the function of TbpB, potentially leading to the
identification of new therapeutic targets. Also, antibodies directed against specific epitopes on
the TbpB protein could have differential effects depending on the location of the epitope. Our
studies have provided insight into the localization of TbpB to the outer membrane and may
potentially be applied to all lipoprotein export in Neisseria and other Gram-negative bacteria
lacking a functional Lol system. Additionally, our studies further characterized the structurefunction relationship of the TbpB lobes, which may be extended to other bilobed, lipid-modified
receptor proteins of Neisseria.

107

Literature Cited

108

Literature Cited

1.

Aisen, P., A. Leibman, and J. Zweier. 1978. Stoichiometric and site characteristics of
the binding of iron to human transferrin. The Journal of Biological Chemistry 253:19301937.

2.

Alcantara, J., and A. B. Schryvers. 1996. Transferrin binding protein two interacts with
both the N-lobe and C-lobe of ovotransferrin. Microbial Pathogenesis 20:73-85.

3.

Alcantara, J., R. H. Yu, and A. B. Schryvers. 1993. The region of human transferrin
involved in binding to bacterial transferrin receptors is localized in the C-lobe. Molecular
Microbiology 8:1135-1143.

4.

Anderson, J. E., M. M. Hobbs, G. D. Biswas, and P. F. Sparling. 2003. Opposing
selective forces for expression of the gonococcal lactoferrin receptor. Molecular
Microbiology 48:1325-1337.

5.

Anderson, J. E., P. F. Sparling, and C. N. Cornelissen. 1994. Gonococcal transferrinbinding protein 2 facilitates but is not essential for transferrin utilization. Journal of
Bacteriology 176:3162-3170.

6.

Archibald, F. S., and I. W. DeVoe. 1980. Iron acquisition by Neisseria meningitidis in
vitro. Infection and Immunity 27:322-334.

7.

Arosio, P., T. G. Adelman, and J. W. Drysdale. 1978. On ferritin heterogeneity.
Further evidence for heteropolymers. The Journal of Biological Chemistry 253:44514458.

8.

Ashford, W. A., R. G. Golash, and V. G. Hemming. 1976. Penicillinase-producing
Neisseria gonorrhoeae. Lancet 2:657-658.

9.

Bala, M., and S. Sood. 2010. Cephalosporin resistance in Neisseria gonorrhoeae.
Journal of Global Infectious Diseases 2:284-290.

10.

Baltes, N., I. Hennig-Pauka, and G. F. Gerlach. 2002. Both transferrin binding proteins
are virulence factors in Actinobacillus pleuropneumoniae serotype 7 infection. FEMS
Microbiology Letters 209:283-287.

11.

Balthazar, J. T., A. Gusa, L. E. Martin, B. Choudhury, R. Carlson, and W. M.
Shafer. 2011. Lipooligosaccharide structure is an important determinant in the resistance
of Neisseria gonorrhoeae to antimicrobial agents of innate host defense. Frontiers in
Microbiology 2:30.

109
12.

Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, and M.
Tomita. 1992. Identification of the bactericidal domain of lactoferrin. Biochimica et
Biophysica Acta 1121:130-136.

13.

Bhat, K. S., C. P. Gibbs, O. Barrera, S. G. Morrison, F. Jahnig, A. Stern, E. M.
Kupsch, T. F. Meyer, and J. Swanson. 1991. The opacity proteins of Neisseria
gonorrhoeae strain MS11 are encoded by a family of 11 complete genes. Molecular
Microbiology 5:1889-1901.

14.

Biswas, G. D., J. E. Anderson, C. J. Chen, C. N. Cornelissen, and P. F. Sparling.
1999. Identification and functional characterization of the Neisseria gonorrhoeae lbpB
gene product. Infection and Immunity 67:455-459.

15.

Biswas, G. D., J. E. Anderson, and P. F. Sparling. 1997. Cloning and functional
characterization of Neisseria gonorrhoeae tonB, exbB and exbD genes. Molecular
Microbiology 24:169-179.

16.

Biswas, G. D., T. Sox, E. Blackman, and P. F. Sparling. 1977. Factors affecting
genetic transformation of Neisseria gonorrhoeae. Journal of Bacteriology 129:983-992.

17.

Biswas, G. D., and P. F. Sparling. 1995. Characterization of lbpA, the structural gene
for a lactoferrin receptor in Neisseria gonorrhoeae. Infection and Immunity 63:29582967.

18.

Bjerknes, R., H. K. Guttormsen, C. O. Solberg, and L. M. Wetzler. 1995. Neisserial
porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor
expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.
Infection and Immunity 63:160-167.

19.

Black, W. J., R. S. Schwalbe, I. Nachamkin, and J. G. Cannon. 1984.
Characterization of Neisseria gonorrhoeae protein II phase variation by use of
monoclonal antibodies. Infection and Immunity 45:453-457.

20.

Blake, M. S., L. M. Wetzler, E. C. Gotschlich, and P. A. Rice. 1989. Protein III:
structure, function, and genetics. Clinical Microbiology Reviews 2 Suppl:S60-63.

21.

Blom, A. M., A. Rytkonen, P. Vasquez, G. Lindahl, B. Dahlback, and A. B. Jonsson.
2001. A novel interaction between type IV pili of Neisseria gonorrhoeae and the human
complement regulator C4B-binding protein. Journal of Immunology 166:6764-6770.

22.

Boisier, P., P. Nicolas, S. Djibo, M. K. Taha, I. Jeanne, H. B. Mainassara, B.
Tenebray, K. K. Kairo, D. Giorgini, and S. Chanteau. 2007. Meningococcal
meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger.
Clinical Infectious Diseases 44:657-663.

23.

Bos, M. P., V. Robert, and J. Tommassen. 2007. Biogenesis of the Gram-negative
bacterial outer membrane. Annual Review of Microbiology 61:191-214.

110
24.

Bos, M. P., and J. Tommassen. 2004. Biogenesis of the Gram-negative bacterial outer
membrane. Current Opinion in Microbiology 7:610-616.

25.

Boslego, J. W., E. C. Tramont, R. C. Chung, D. G. McChesney, J. Ciak, J. C. Sadoff,
M. V. Piziak, J. D. Brown, C. C. Brinton, Jr., S. W. Wood, and et al. 1991. Efficacy
trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9:154-162.

26.

Boulton, I. C., A. R. Gorringe, N. Allison, A. Robinson, B. Gorinsky, C. L. Joannou,
and R. W. Evans. 1998. Transferrin-binding protein B isolated from Neisseria
meningitidis discriminates between apo and diferric human transferrin. The Biochemical
Journal 334 ( Pt 1):269-273.

27.

Boulton, I. C., M. K. Yost, J. E. Anderson, and C. N. Cornelissen. 2000. Identification
of discrete domains within gonococcal transferrin-binding protein A that are necessary
for ligand binding and iron uptake functions. Infection and Immunity 68:6988-6996.

28.

Bovre, K. 1984. Family VIII. Neisseriaceae Prevot, p. 288-309, Manual of Systematic
Bacteriology, In N. R. Krieg ed, vol. 1. The Williams & Wilkins co., Baltimore.

29.

Briat, J. F. 1992. Iron assimilation and storage in prokaryotes. Journal of General
Microbiology 138:2475-2483.

30.

Brock, J. 1995. Lactoferrin: a multifunctional immunoregulatory protein? Immunology
Today 16:417-419.

31.

Brock, J. H. 2002. The physiology of lactoferrin. Biochemistry and Cell Biology 80:1-6.

32.

Calmettes, C., J. Alcantara, R. H. Yu, A. B. Schryvers, and T. F. Moraes. 2012. The
structural basis of transferrin sequestration by transferrin-binding protein B. Nature
Structural & Molecular Biology 19:358-360.

33.

Carson, S. D., P. E. Klebba, S. M. Newton, and P. F. Sparling. 1999. Ferric
enterobactin binding and utilization by Neisseria gonorrhoeae. Journal of Bacteriology
181:2895-2901.

34.

Cartwright, K. A., J. M. Stuart, D. M. Jones, and N. D. Noah. 1987. The Stonehouse
survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiology
and Infection 99:591-601.

35.

Caugant, D. A., and M. C. Maiden. 2009. Meningococcal carriage and disease-population biology and evolution. Vaccine 27 Suppl 2:B64-70.

36.

CDC. 2005. Prevention and control of meningococcal disease: recommendations of the
Advisory Committee on immunization practices (ACIP). Morbidity and Mortality
Weekly Report 54:1-21.

37.

CDC. 2010. Sexually transmitted disease surveillance 2010, gonococcal isolate
surveillance project (GISP) national profile.

111
38.

CDC. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006:
fluoroquinolones no longer recommended for treatment of gonococcal infections.
Morbidity and Mortality Weekly Report 56:332-336.

39.

Chasteen, N. D., and J. Williams. 1981. The influence of pH on the equilibrium
distribution of iron between the metal-binding sites of human transferrin. The
Biochemical Journal 193:717-727.

40.

Chen, A., I. C. Boulton, J. Pongoski, A. Cochrane, and S. D. Gray-Owen. 2003.
Induction of HIV-1 long terminal repeat-mediated transcription by Neisseria
gonorrhoeae. AIDS 17:625-628.

41.

Chen, C. J., C. Elkins, and P. F. Sparling. 1998. Phase variation of hemoglobin
utilization in Neisseria gonorrhoeae. Infection and Immunity 66:987-993.

42.

Chen, C. J., P. F. Sparling, L. A. Lewis, D. W. Dyer, and C. Elkins. 1996.
Identification and purification of a hemoglobin-binding outer membrane protein from
Neisseria gonorrhoeae. Infection and Immunity 64:5008-5014.

43.

Chen, C. Y., S. A. Berish, S. A. Morse, and T. A. Mietzner. 1993. The ferric ironbinding protein of pathogenic Neisseria spp. functions as a periplasmic transport protein
in iron acquisition from human transferrin. Molecular Microbiology 10:311-318.

44.

Chen, T., and E. C. Gotschlich. 1996. CGM1a antigen of neutrophils, a receptor of
gonococcal opacity proteins. Proceedings of the National Academy of Sciences of the
United States of America 93:14851-14856.

45.

Cohen, M. S., I. F. Hoffman, R. A. Royce, P. Kazembe, J. R. Dyer, C. C. Daly, D.
Zimba, P. L. Vernazza, M. Maida, S. A. Fiscus, and J. J. Eron, Jr. 1997. Reduction of
concentration of HIV-1 in semen after treatment of urethritis: implications for prevention
of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 349:18681873.

46.

Cornelissen, C. N., J. E. Anderson, I. C. Boulton, and P. F. Sparling. 2000. Antigenic
and sequence diversity in gonococcal transferrin-binding protein A. Infection and
Immunity 68:4725-4735.

47.

Cornelissen, C. N., J. E. Anderson, and P. F. Sparling. 1997. Characterization of the
diversity and the transferrin-binding domain of gonococcal transferrin-binding protein 2.
Infection and Immunity 65:822-828.

48.

Cornelissen, C. N., J. E. Anderson, and P. F. Sparling. 1997. Energy-dependent
changes in the gonococcal transferrin receptor. Molecular Microbiology 26:25-35.

49.

Cornelissen, C. N., G. D. Biswas, J. Tsai, D. K. Paruchuri, S. A. Thompson, and P.
F. Sparling. 1992. Gonococcal transferrin-binding protein 1 is required for transferrin
utilization and is homologous to TonB-dependent outer membrane receptors. Journal of
Bacteriology 174:5788-5797.

112
50.

Cornelissen, C. N., M. Kelley, M. M. Hobbs, J. E. Anderson, J. G. Cannon, M. S.
Cohen, and P. F. Sparling. 1998. The transferrin receptor expressed by gonococcal
strain FA1090 is required for the experimental infection of human male volunteers.
Molecular Microbiology 27:611-616.

51.

Cornelissen, C. N., and P. F. Sparling. 1996. Binding and surface exposure
characteristics of the gonococcal transferrin receptor are dependent on both transferrinbinding proteins. Journal of Bacteriology 178:1437-1444.

52.

Coutte, L., E. Willery, R. Antoine, H. Drobecq, C. Locht, and F. Jacob-Dubuisson.
2003. Surface anchoring of bacterial subtilisin important for maturation function.
Molecular Microbiology 49:529-539.

53.

Criss, A. K., K. A. Kline, and H. S. Seifert. 2005. The frequency and rate of pilin
antigenic variation in Neisseria gonorrhoeae. Molecular Microbiology 58:510-519.

54.

d'Enfert, C., C. Chapon, and A. P. Pugsley. 1987. Export and secretion of the
lipoprotein pullulanase by Klebsiella pneumoniae. Molecular Microbiology 1:107-116.

55.

Danaher, R. J., J. C. Levin, D. Arking, C. L. Burch, R. Sandlin, and D. C. Stein.
1995. Genetic basis of Neisseria gonorrhoeae lipooligosaccharide antigenic variation.
Journal of Bacteriology 177:7275-7279.

56.

Delanghe, J. R., and M. R. Langlois. 2001. Hemopexin: a review of biological aspects
and the role in laboratory medicine. Clinica Chimica Acta 312:13-23.

57.

DeRocco, A. J., and C. N. Cornelissen. 2007. Identification of transferrin-binding
domains in TbpB expressed by Neisseria gonorrhoeae. Infection and Immunity 75:32203232.

58.

DeRocco, A. J., M. K. Yost-Daljev, C. D. Kenney, and C. N. Cornelissen. 2009.
Kinetic analysis of ligand interaction with the gonococcal transferrin-iron acquisition
system. Biometals 22:439-451.

59.

Derrick, J. P., R. Urwin, J. Suker, I. M. Feavers, and M. C. Maiden. 1999. Structural
and evolutionary inference from molecular variation in Neisseria porins. Infection and
Immunity 67:2406-2413.

60.

Dunlop, E. M. 1949. Gonorrhoea and the sulphonamides. The British Journal of
Venereal Diseases 25:81-83.

61.

Edwards, J. L., E. J. Brown, K. A. Ault, and M. A. Apicella. 2001. The role of
complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical
epithelia. Cellular Microbiology 3:611-622.

62.

Faraldo-Gomez, J. D., and M. S. Sansom. 2003. Acquisition of siderophores in Gramnegative bacteria. Nature Reviews. Molecular Cell Biology 4:105-116.

113
63.

Farnaud, S., and R. W. Evans. 2003. Lactoferrin--a multifunctional protein with
antimicrobial properties. Molecular Immunology 40:395-405.

64.

Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. Serotype antigens of
Neisseria meningitidis and a proposed scheme for designation of serotypes. Reviews of
Infectious Diseases 7:504-510.

65.

Frost, G. E., and H. Rosenberg. 1973. The inducible citrate-dependent iron transport
system in Escherichia coli K12. Biochimica et Biophysica Acta 330:90-101.

66.

Garby, L., and W. D. Noyes. 1959. Studies on hemoglobin metabolism. I. The kinetic
properties of the plasma hemoglobin pool in normal man. The Journal of Clinical
Investigation 38:1479-1483.

67.

Gennity, J. M., and M. Inouye. 1991. The protein sequence responsible for lipoprotein
membrane localization in Escherichia coli exhibits remarkable specificity. The Journal of
Biological Chemistry 266:16458-16464.

68.

Gomez-Duarte, O. G., M. Dehio, C. A. Guzman, G. S. Chhatwal, C. Dehio, and T. F.
Meyer. 1997. Binding of vitronectin to opa-expressing Neisseria gonorrhoeae mediates
invasion of HeLa cells. Infection and Immunity 65:3857-3866.

69.

Gotschlich, E. C., M. S. Blake, E. J. Lytton, and M. Seiff. 1987. Gonococcal protein
III. Purification and chemical characterization of the protein, and the DNA sequence of
the structural gene. Antonie van Leeuwenhoek 53:455-459.

70.

Gotschlich, E. C., M. Seiff, and M. S. Blake. 1987. The DNA sequence of the structural
gene of gonococcal protein III and the flanking region containing a repetitive sequence.
Homology of protein III with enterobacterial OmpA proteins. The Journal of
Experimental Medicine 165:471-482.

71.

Gotschlich, E. C., M. E. Seiff, M. S. Blake, and M. Koomey. 1987. Porin protein of
Neisseria gonorrhoeae: cloning and gene structure. Proceedings of the National
Academy of Sciences of the United States of America 84:8135-8139.

72.

Grassme, H. U., R. M. Ireland, and J. P. van Putten. 1996. Gonococcal opacity
protein promotes bacterial entry-associated rearrangements of the epithelial cell actin
cytoskeleton. Infection and Immunity 64:1621-1630.

73.

Greenwood, B. 1999. Manson Lecture. Meningococcal meningitis in Africa.
Transactions of the Royal Society of Tropical Medicine and Hygiene 93:341-353.

74.

Haake, D. A. 2000. Spirochaetal lipoproteins and pathogenesis. Microbiology 146 ( Pt
7):1491-1504.

75.

Haas, R., and T. F. Meyer. 1986. The repertoire of silent pilus genes in Neisseria
gonorrhoeae: evidence for gene conversion. Cell 44:107-115.

114
76.

Hagblom, P., E. Segal, E. Billyard, and M. So. 1985. Intragenic recombination leads to
pilus antigenic variation in Neisseria gonorrhoeae. Nature 315:156-158.

77.

Hagen, T. A. 2006. Mechanisms of iron acquisition employed by Neisseria gonorrhoeae
for survival within cervical epithelial cells. Dissertation. Virginia Commonwealth
University, Richmond, VA.

78.

Hammer, N. D., and E. P. Skaar. 2011. Molecular mechanisms of Staphylococcus
aureus iron acquisition. Annual Review of Microbiology 65:129-147.

79.

Harrison, L. H. 2010. Epidemiological profile of meningococcal disease in the United
States. Clinical Infectious Diseases : an official publication of the Infectious Diseases
Society of America 50 Suppl 2:S37-44.

80.

Harrison, L. H. 2006. Prospects for vaccine prevention of meningococcal infection.
Clinical Microbiology Reviews 19:142-164.

81.

Harrison, P. M., and P. Arosio. 1996. The ferritins: molecular properties, iron storage
function and cellular regulation. Biochimica et Biophysica Acta 1275:161-203.

82.

Hauck, C. R., and T. F. Meyer. 1997. The lysosomal/phagosomal membrane protein hlamp-1 is a target of the IgA1 protease of Neisseria gonorrhoeae. FEBS Letters 405:8690.

83.

Hayashi, S., and H. C. Wu. 1990. Lipoproteins in bacteria. Journal of Bioenergetics and
Biomembranes 22:451-471.

84.

Heckels, J. E., B. Blackett, J. S. Everson, and M. E. Ward. 1976. The influence of
surface charge on the attachment of Neisseria gonorrhoeae to human cells. Journal of
General Microbiology 96:359-364.

85.

Hegge, F. T., P. G. Hitchen, F. E. Aas, H. Kristiansen, C. Lovold, W. Egge-Jacobsen,
M. Panico, W. Y. Leong, V. Bull, M. Virji, H. R. Morris, A. Dell, and M. Koomey.
2004. Unique modifications with phosphocholine and phosphoethanolamine define
alternate antigenic forms of Neisseria gonorrhoeae type IV pili. Proceedings of the
National Academy of Sciences of the United States of America 101:10798-10803.

86.

Hitchcock, P. J. 1984. Analyses of gonococcal lipopolysaccharide in whole-cell lysates
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis: stable association of
lipopolysaccharide with the major outer membrane protein (protein I) of Neisseria
gonorrhoeae. Infection and Immunity 46:202-212.

87.

Hollander, A., A. D. Mercante, W. M. Shafer, and C. N. Cornelissen. 2011. The ironrepressed, AraC-like regulator MpeR activates expression of fetA in Neisseria
gonorrhoeae. Infection and Immunity 79:4764-4776.

88.

Holmes, K. K., G. W. Counts, and H. N. Beaty. 1971. Disseminated gonococcal
infection. Annals of Internal Medicine 74:979-993.

115
89.

Hopper, S., B. Vasquez, A. Merz, S. Clary, J. S. Wilbur, and M. So. 2000. Effects of
the immunoglobulin A1 protease on Neisseria gonorrhoeae trafficking across polarized
T84 epithelial monolayers. Infection and Immunity 68:906-911.

90.

Hussein, S., K. Hantke, and V. Braun. 1981. Citrate-dependent iron transport system in
Escherichia coli K-12. European Journal of Biochemistry 117:431-437.

91.

Husson, M. O., D. Legrand, G. Spik, and H. Leclerc. 1993. Iron acquisition by
Helicobacter pylori: importance of human lactoferrin. Infection and Immunity 61:26942697.

92.

Jerse, A. E., M. S. Cohen, P. M. Drown, L. G. Whicker, S. F. Isbey, H. S. Seifert,
and J. G. Cannon. 1994. Multiple gonococcal opacity proteins are expressed during
experimental urethral infection in the male. The Journal of Experimental Medicine
179:911-920.

93.

Johannsen, D. B., D. M. Johnston, H. O. Koymen, M. S. Cohen, and J. G. Cannon.
1999. A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the
human challenge model of urethral infection. Infection and Immunity 67:3009-3013.

94.

Joiner, K. A., R. Scales, K. A. Warren, M. M. Frank, and P. A. Rice. 1985.
Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. The
Journal of Clinical Investigation 76:1765-1772.

95.

Jonsson, A. B., G. Nyberg, and S. Normark. 1991. Phase variation of gonococcal pili
by frameshift mutation in pilC, a novel gene for pilus assembly. The EMBO Journal
10:477-488.

96.

Kallstrom, H., M. K. Liszewski, J. P. Atkinson, and A. B. Jonsson. 1997. Membrane
cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria.
Molecular Microbiology 25:639-647.

97.

Kampmeier, R. H. 1983. Introduction of sulfonamide therapy for gonorrhea. Sexually
Transmitted Diseases 10:81-84.

98.

Kellogg, D. S., Jr., I. R. Cohen, L. C. Norins, A. L. Schroeter, and G. Reising. 1968.
Neisseria gonorrhoeae. II. Colonial variation and pathogenicity during 35 months in
vitro. Journal of Bacteriology 96:596-605.

99.

Kenney, C. D., and C. N. Cornelissen. 2002. Demonstration and characterization of a
specific interaction between gonococcal transferrin binding protein A and TonB. Journal
of Bacteriology 184:6138-6145.

100.

Klein, E. J., L. S. Fisher, A. W. Chow, and L. B. Guze. 1977. Anorectal gonococcal
infection. Annals of Internal Medicine 86:340-346.

101.

Knapp, J. S. 1988. Historical perspectives and identification of Neisseria and related
species. Clinical Microbiology Reviews 1:415-431.

116
102.

Koomey, M., E. C. Gotschlich, K. Robbins, S. Bergstrom, and J. Swanson. 1987.
Effects of recA mutations on pilus antigenic variation and phase transitions in Neisseria
gonorrhoeae. Genetics 117:391-398.

103.

Kovacs-Simon, A., R. W. Titball, and S. L. Michell. 2011. Lipoproteins of bacterial
pathogens. Infection and Immunity 79:548-561.

104.

Kristiansen, M., J. H. Graversen, C. Jacobsen, O. Sonne, H. J. Hoffman, S. K. Law,
and S. K. Moestrup. 2001. Identification of the haemoglobin scavenger receptor. Nature
409:198-201.

105.

Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227:680-685.

106.

Larsen, R. A., D. Foster-Hartnett, M. A. McIntosh, and K. Postle. 1997. Regions of
Escherichia coli TonB and FepA proteins essential for in vivo physical interactions.
Journal of Bacteriology 179:3213-3221.

107.

Lebedenko, E. N., K. R. Birikh, O. V. Plutalov, and A. Berlin Yu. 1991. Method of
artificial DNA splicing by directed ligation (SDL). Nucleic Acids Research 19:67576761.

108.

Legrain, M., V. Mazarin, S. W. Irwin, B. Bouchon, M. J. Quentin-Millet, E. Jacobs,
and A. B. Schryvers. 1993. Cloning and characterization of Neisseria meningitidis genes
encoding the transferrin-binding proteins Tbp1 and Tbp2. Gene 130:73-80.

109.

Lewis, L. A., and D. W. Dyer. 1995. Identification of an iron-regulated outer membrane
protein of Neisseria meningitidis involved in the utilization of hemoglobin complexed to
haptoglobin. Journal of Bacteriology 177:1299-1306.

110.

Lewis, L. A., M. Gipson, K. Hartman, T. Ownbey, J. Vaughn, and D. W. Dyer. 1999.
Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria
meningitidis DNM2. Molecular Microbiology 32:977-989.

111.

Lewis, L. A., E. Gray, Y. P. Wang, B. A. Roe, and D. W. Dyer. 1997. Molecular
characterization of hpuAB, the haemoglobin-haptoglobin-utilization operon of Neisseria
meningitidis. Molecular Microbiology 23:737-749.

112.

Lin, L., P. Ayala, J. Larson, M. Mulks, M. Fukuda, S. R. Carlsson, C. Enns, and M.
So. 1997. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of
bacteria within epithelial cells. Molecular Microbiology 24:1083-1094.

113.

Lissolo, L., G. Maitre-Wilmotte, P. Dumas, M. Mignon, B. Danve, and M. J.
Quentin-Millet. 1995. Evaluation of transferrin-binding protein 2 within the transferrinbinding protein complex as a potential antigen for future meningococcal vaccines.
Infection and Immunity 63:884-890.

117
114.

Luck, S. N., S. A. Turner, K. Rajakumar, H. Sakellaris, and B. Adler. 2001. Ferric
dicitrate transport system (Fec) of Shigella flexneri 2a YSH6000 is encoded on a novel
pathogenicity island carrying multiple antibiotic resistance genes. Infection and Immunity
69:6012-6021.

115.

Lynch, E. C., M. S. Blake, E. C. Gotschlich, and A. Mauro. 1984. Studies of porins:
spontaneously transferred from whole cells and reconstituted from purified proteins of
Neisseria gonorrhoeae and Neisseria meningitidis. Biophysical Journal 45:104-107.

116.

Lytton, E. J., and M. S. Blake. 1986. Isolation and partial characterization of the
reduction-modifiable protein of Neisseria gonorrhoeae. The Journal of Experimental
medicine 164:1749-1759.

117.

MacGillivray, R. T., E. Mendez, J. G. Shewale, S. K. Sinha, J. Lineback-Zins, and
K. Brew. 1983. The primary structure of human serum transferrin. The structures of
seven cyanogen bromide fragments and the assembly of the complete structure. The
Journal of Biological Chemistry 258:3543-3553.

118.

MacNeil, J., and A. C. Cohn. 2011. Meningococcal disease, Manual for the Surveillance
of Vaccine-Preventable Diseases, 5 ed. CDC, Atlanta, GA.

119.

Mahoney, J. F., C. Ferguson, M. Buchholtz, and C. J. van Slyke. 1943. The use of
penicillin sodium in the treatment of sulfonamide-resistance gonorrhea in men. A
preliminary report. Am J Syph Gonorrhea Vener Dis 27:525-528.

120.

Malorny, B., G. Morelli, B. Kusecek, J. Kolberg, and M. Achtman. 1998. Sequence
diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial
Opa proteins. Journal of Bacteriology 180:1323-1330.

121.

Mandrell, R. E., and M. A. Apicella. 1993. Lipo-oligosaccharides (LOS) of mucosal
pathogens: molecular mimicry and host-modification of LOS. Immunobiology 187:382402.

122.

Mariller, C., M. Benaissa, S. Hardiville, M. Breton, G. Pradelle, J. Mazurier, and A.
Pierce. 2007. Human delta-lactoferrin is a transcription factor that enhances Skp1 (Sphase kinase-associated protein) gene expression. The FEBS Journal 274:2038-2053.

123.

Matsuyama, S., T. Tajima, and H. Tokuda. 1995. A novel periplasmic carrier protein
involved in the sorting and transport of Escherichia coli lipoproteins destined for the
outer membrane. The EMBO Journal 14:3365-3372.

124.

Matsuyama, S., N. Yokota, and H. Tokuda. 1997. A novel outer membrane
lipoprotein, LolB (HemM), involved in the LolA (p20)-dependent localization of
lipoproteins to the outer membrane of Escherichia coli. The EMBO Journal 16:69476955.

125.

Mazarin, V., B. Rokbi, and M. J. Quentin-Millet. 1995. Diversity of the transferrinbinding protein Tbp2 of Neisseria meningitidis. Gene 158:145-146.

118
126.

McClelland, R. S., C. C. Wang, K. Mandaliya, J. Overbaugh, M. T. Reiner, D. D.
Panteleeff, L. Lavreys, J. Ndinya-Achola, J. J. Bwayo, and J. K. Kreiss. 2001.
Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS
15:105-110.

127.

McDade, R. L., Jr., and K. H. Johnston. 1980. Characterization of serologically
dominant outer membrane proteins of Neisseria gonorrhoeae. Journal of Bacteriology
141:1183-1191.

128.

Merz, A. J., M. So, and M. P. Sheetz. 2000. Pilus retraction powers bacterial twitching
motility. Nature 407:98-102.

129.

Meyer, T. F., N. Mlawer, and M. So. 1982. Pilus expression in Neisseria gonorrhoeae
involves chromosomal rearrangement. Cell 30:45-52.

130.

Mickelsen, P. A., and P. F. Sparling. 1981. Ability of Neisseria gonorrhoeae, Neisseria
meningitidis, and commensal Neisseria species to obtain iron from transferrin and iron
compounds. Infection and Immunity 33:555-564.

131.

Moeck, G. S., and L. Letellier. 2001. Characterization of in vitro interactions between a
truncated TonB protein from Escherichia coli and the outer membrane receptors FhuA
and FepA. Journal of Bacteriology 183:2755-2764.

132.

Moraes, T. F., R. H. Yu, N. C. Strynadka, and A. B. Schryvers. 2009. Insights into the
bacterial transferrin receptor: the structure of transferrin-binding protein B from
Actinobacillus pleuropneumoniae. Molecular Cell 35:523-533.

133.

Mori, H., and K. Ito. 2001. The Sec protein-translocation pathway. Trends in
Microbiology 9:494-500.

134.

Morrow, G. L., and R. L. Abbott. 1998. Conjunctivitis. American Family Physician
57:735-746.

135.

Mosleh, I. M., L. A. Huber, P. Steinlein, C. Pasquali, D. Gunther, and T. F. Meyer.
1998. Neisseria gonorrhoeae porin modulates phagosome maturation. The Journal of
Biological Chemistry 273:35332-35338.

136.

Muller, A., D. Gunther, F. Dux, M. Naumann, T. F. Meyer, and T. Rudel. 1999.
Neisserial porin (PorB) causes rapid calcium influx in target cells and induces apoptosis
by the activation of cysteine proteases. The EMBO Journal 18:339-352.

137.

Murakami, K., E. C. Gotschlich, and M. E. Seiff. 1989. Cloning and characterization
of the structural gene for the class 2 protein of Neisseria meningitidis. Infection and
Immunity 57:2318-2323.

138.

Murphy, G. L., T. D. Connell, D. S. Barritt, M. Koomey, and J. G. Cannon. 1989.
Phase variation of gonococcal protein II: regulation of gene expression by slipped-strand
mispairing of a repetitive DNA sequence. Cell 56:539-547.

119
139.

Myers, L. E., Y. P. Yang, R. P. Du, Q. Wang, R. E. Harkness, A. B. Schryvers, M. H.
Klein, and S. M. Loosmore. 1998. The transferrin binding protein B of Moraxella
catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen. Infection and
Immunity 66:4183-4192.

140.

Nairn, C. A., J. A. Cole, P. V. Patel, N. J. Parsons, J. E. Fox, and H. Smith. 1988.
Cytidine 5'-monophospho-N-acetylneuraminic acid or a related compound is the low Mr
factor from human red blood cells which induces gonococcal resistance to killing by
human serum. Journal of General Microbiology 134:3295-3306.

141.

Narita, S., S. Matsuyama, and H. Tokuda. 2004. Lipoprotein trafficking in Escherichia
coli. Archives of Microbiology 182:1-6.

142.

Narita, S., K. Tanaka, S. Matsuyama, and H. Tokuda. 2002. Disruption of lolCDE,
encoding an ATP-binding cassette transporter, is lethal for Escherichia coli and prevents
release of lipoproteins from the inner membrane. Journal of Bacteriology 184:1417-1422.

143.

Narita, S., and H. Tokuda. 2006. An ABC transporter mediating the membrane
detachment of bacterial lipoproteins depending on their sorting signals. FEBS Letters
580:1164-1170.

144.

Ng, L. K., and I. E. Martin. 2005. The laboratory diagnosis of Neisseria gonorrhoeae.
The Canadian Journal of Infectious Diseases and Medical Microbiology 16:15-25.

145.

Nielsen, M. J., and S. K. Moestrup. 2009. Receptor targeting of hemoglobin mediated
by the haptoglobins: roles beyond heme scavenging. Blood 114:764-771.

146.

Noinaj, N., N. C. Easley, M. Oke, N. Mizuno, J. Gumbart, E. Boura, A. N. Steere, O.
Zak, P. Aisen, E. Tajkhorshid, R. W. Evans, A. R. Gorringe, A. B. Mason, A. C.
Steven, and S. K. Buchanan. 2012. Structural basis for iron piracy by pathogenic
Neisseria. Nature 483:53-58.

147.

Ohnishi, M., T. Saika, S. Hoshina, K. Iwasaku, S. Nakayama, H. Watanabe, and J.
Kitawaki. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerging
Infectious Diseases 17:148-149.

148.

Parge, H. E., K. T. Forest, M. J. Hickey, D. A. Christensen, E. D. Getzoff, and J. A.
Tainer. 1995. Structure of the fibre-forming protein pilin at 2.6 A resolution. Nature
378:32-38.

149.

Pelicic, V., S. Morelle, D. Lampe, and X. Nassif. 2000. Mutagenesis of Neisseria
meningitidis by in vitro transposition of Himar1 mariner. Journal of Bacteriology
182:5391-5398.

150.

Phillips, I. 1976. Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet
2:656-657.

120
151.

Pintor, M., L. Ferron, J. A. Gomez, A. Gorringe, M. T. Criado, and C. M. Ferreiros.
1996. Blocking of iron uptake by monoclonal antibodies specific for the Neisseria
meningitidis transferrin-binding protein 2. Journal of Medical Microbiology 45:252-257.

152.

Pintor, M., L. Ferron, J. A. Gomez, N. B. Powell, D. A. Ala'Aldeen, S. P. Borriello,
M. T. Criado, and C. M. Ferreiros. 1996. Blocking of iron uptake from transferrin by
antibodies against the transferrin binding proteins in Neisseria meningitidis. Microbial
Pathogenesis 20:127-139.

153.

Plaut, A. G., J. V. Gilbert, M. S. Artenstein, and J. D. Capra. 1975. Neisseria
gonorrhoeae and Neisseria meningitidis: extracellular enzyme cleaves human
immunoglobulin A. Science 190:1103-1105.

154.

Plummer, F. A., H. Chubb, J. N. Simonsen, M. Bosire, L. Slaney, I. Maclean, J. O.
Ndinya-Achola, P. Waiyaki, and R. C. Brunham. 1993. Antibody to Rmp (outer
membrane protein 3) increases susceptibility to gonococcal infection. The Journal of
Clinical Investigation 91:339-343.

155.

Price, G. A., M. M. Hobbs, and C. N. Cornelissen. 2004. Immunogenicity of
gonococcal transferrin binding proteins during natural infections. Infection and Immunity
72:277-283.

156.

Price, G. A., M. W. Russell, and C. N. Cornelissen. 2005. Intranasal administration of
recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to
the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infection
and Immunity 73:3945-3953.

157.

Pugsley, A. P. 1993. The complete general secretory pathway in Gram-negative bacteria.
Microbiological Reviews 57:50-108.

158.

Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, B. G. Monks, C.
O'Connell, R. Boden, C. Elkins, M. K. Pangburn, B. Dahlback, and P. A. Rice. 2001.
Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of
Neisseria gonorrhoeae. The Journal of Experimental Medicine 193:281-295.

159.

Ram, S., D. P. McQuillen, S. Gulati, C. Elkins, M. K. Pangburn, and P. A. Rice.
1998. Binding of complement factor H to loop 5 of porin protein 1A: a molecular
mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. The Journal of
Experimental Medicine 188:671-680.

160.

Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen, M. K. Pangburn,
and P. A. Rice. 1998. A novel sialic acid binding site on factor H mediates serum
resistance of sialylated Neisseria gonorrhoeae. The Journal of Experimental Medicine
187:743-752.

161.

Ratledge, C., and L. G. Dover. 2000. Iron metabolism in pathogenic bacteria. Annual
Review of Microbiology 54:881-941.

121
162.

Renauld-Mongenie, G., D. Poncet, L. von Olleschik-Elbheim, T. Cournez, M.
Mignon, M. A. Schmidt, and M. J. Quentin-Millet. 1997. Identification of human
transferrin-binding sites within meningococcal transferrin-binding protein B. Journal of
Bacteriology 179:6400-6407.

163.

Retzer, M. D., A. Kabani, L. L. Button, R. H. Yu, and A. B. Schryvers. 1996.
Production and characterization of chimeric transferrins for the determination of the
binding domains for bacterial transferrin receptors. The Journal of Biological Chemistry
271:1166-1173.

164.

Retzer, M. D., R. H. Yu, and A. B. Schryvers. 1999. Identification of sequences in
human transferrin that bind to the bacterial receptor protein, transferrin-binding protein
B. Molecular Microbiology 32:111-121.

165.

Rice, P. A., H. E. Vayo, M. R. Tam, and M. S. Blake. 1986. Immunoglobulin G
antibodies directed against protein III block killing of serum-resistant Neisseria
gonorrhoeae by immune serum. The Journal of Experimental Medicine 164:1735-1748.

166.

Richardson, A. R., and I. Stojiljkovic. 1999. HmbR, a hemoglobin-binding outer
membrane protein of Neisseria meningitidis, undergoes phase variation. Journal of
Bacteriology 181:2067-2074.

167.

Rokbi, B., G. Maitre-Wilmotte, V. Mazarin, L. Fourrichon, L. Lissolo, and M. J.
Quentin-Millet. 1995. Variable sequences in a mosaic-like domain of meningococcal
tbp2 encode immunoreactive epitopes. FEMS Microbiology Letters 132:277-283.

168.

Rokbi, B., M. Mignon, G. Maitre-Wilmotte, L. Lissolo, B. Danve, D. A. Caugant,
and M. J. Quentin-Millet. 1997. Evaluation of recombinant transferrin-binding protein
B variants from Neisseria meningitidis for their ability to induce cross-reactive and
bactericidal antibodies against a genetically diverse collection of serogroup B strains.
Infection and Immunity 65:55-63.

169.

Ronpirin, C., A. E. Jerse, and C. N. Cornelissen. 2001. Gonococcal genes encoding
transferrin-binding proteins A and B are arranged in a bicistronic operon but are subject
to differential expression. Infection and Immunity 69:6336-6347.

170.

Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001.
Meningococcal disease. The New England Journal of Medicine 344:1378-1388.

171.

Rossi-Campos, A., C. Anderson, G. F. Gerlach, S. Klashinsky, A. A. Potter, and P. J.
Willson. 1992. Immunization of pigs against Actinobacillus pleuropneumoniae with two
recombinant protein preparations. Vaccine 10:512-518.

172.

Rother, R. P., L. Bell, P. Hillmen, and M. T. Gladwin. 2005. The clinical sequelae of
intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of
human disease. The Journal of the American Medical Association 293:1653-1662.

122
173.

Rudel, T., I. Scheurerpflug, and T. F. Meyer. 1995. Neisseria PilC protein identified as
type-4 pilus tip-located adhesin. Nature 373:357-359.

174.

Rudel, T., A. Schmid, R. Benz, H. A. Kolb, F. Lang, and T. F. Meyer. 1996.
Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: parallels
between pathogen accommodation and mitochondrial endosymbiosis. Cell 85:391-402.

175.

Sadrzadeh, S. M., E. Graf, S. S. Panter, P. E. Hallaway, and J. W. Eaton. 1984.
Hemoglobin. A biologic fenton reagent. The Journal of Biological Chemistry 259:1435414356.

176.

Saez-Llorens, X., and G. H. McCracken, Jr. 2003. Bacterial meningitis in children.
Lancet 361:2139-2148.

177.

Sanchez, L., M. Calvo, and J. H. Brock. 1992. Biological role of lactoferrin. Archives
of Disease in Childhood 67:657-661.

178.

Sankaran, K., and H. C. Wu. 1994. Lipid modification of bacterial prolipoprotein.
Transfer of diacylglyceryl moiety from phosphatidylglycerol. The Journal of Biological
Chemistry 269:19701-19706.

179.

Schryvers, A. B., and S. Gray-Owen. 1992. Iron acquisition in Haemophilus influenzae:
receptors for human transferrin. The Journal of Infectious Diseases 165 Suppl 1:S103104.

180.

Schryvers, A. B., and B. C. Lee. 1989. Comparative analysis of the transferrin and
lactoferrin binding proteins in the family Neisseriaceae. Canadian Journal of
Microbiology 35:409-415.

181.

Schryvers, A. B., and L. J. Morris. 1988. Identification and characterization of the
transferrin receptor from Neisseria meningitidis. Molecular Microbiology 2:281-288.

182.

Skaar, E. P. 2010. The battle for iron between bacterial pathogens and their vertebrate
hosts. PLoS Pathogens 6:e1000949.

183.

Smith, A., and W. T. Morgan. 1979. Haem transport to the liver by haemopexin.
Receptor-mediated uptake with recycling of the protein. The Biochemical Journal
182:47-54.

184.

Sparling, P. F. 1966. Genetic transformation of Neisseria gonorrhoeae to streptomycin
resistance. Journal of Bacteriology 92:1364-1371.

185.

Stathopoulos, C., D. R. Hendrixson, D. G. Thanassi, S. J. Hultgren, J. W. St Geme,
3rd, and R. Curtiss, 3rd. 2000. Secretion of virulence determinants by the general
secretory pathway in Gram-negative pathogens: an evolving story. Microbes and
Infection 2:1061-1072.

123
186.

Staudenmaier, H., B. Van Hove, Z. Yaraghi, and V. Braun. 1989. Nucleotide
sequences of the fecBCDE genes and locations of the proteins suggest a periplasmicbinding-protein-dependent transport mechanism for iron(III) dicitrate in Escherichia coli.
Journal of Bacteriology 171:2626-2633.

187.

Stephens, D. S. 1999. Uncloaking the meningococcus: dynamics of carriage and disease.
Lancet 353:941-942.

188.

Stephens, D. S., B. Greenwood, and P. Brandtzaeg. 2007. Epidemic meningitis,
meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210.

189.

Stephens, D. S., and Z. A. McGee. 1981. Attachment of Neisseria meningitidis to
human mucosal surfaces: influence of pili and type of receptor cell. The Journal of
Infectious Diseases 143:525-532.

190.

Stern, A., and T. F. Meyer. 1987. Common mechanism controlling phase and antigenic
variation in pathogenic Neisseriae. Molecular Microbiology 1:5-12.

191.

Stevenson, P., P. Williams, and E. Griffiths. 1992. Common antigenic domains in
transferrin-binding protein 2 of Neisseria meningitidis, Neisseria gonorrhoeae, and
Haemophilus influenzae type b. Infection and Immunity 60:2391-2396.

192.

Stojiljkovic, I., V. Hwa, L. de Saint Martin, P. O'Gaora, X. Nassif, F. Heffron, and
M. So. 1995. The Neisseria meningitidis haemoglobin receptor: its role in iron utilization
and virulence. Molecular Microbiology 15:531-541.

193.

Stojiljkovic, I., J. Larson, V. Hwa, S. Anic, and M. So. 1996. HmbR outer membrane
receptors of pathogenic Neisseria spp.: iron-regulated, hemoglobin-binding proteins with
a high level of primary structure conservation. Journal of Bacteriology 178:4670-4678.

194.

Stojiljkovic, I., and N. Srinivasan. 1997. Neisseria meningitidis tonB, exbB, and exbD
genes: Ton-dependent utilization of protein-bound iron in Neisseriae. Journal of
Bacteriology 179:805-812.

195.

Strange, H. R., T. A. Zola, and C. N. Cornelissen. 2011. The fbpABC operon is
required for Ton-independent utilization of xenosiderophores by Neisseria gonorrhoeae
strain FA19. Infection and Immunity 79:267-278.

196.

Swanson, J. 1973. Studies on gonococcus infection. IV. Pili: their role in attachment of
gonococci to tissue culture cells. The Journal of Experimental Medicine 137:571-589.

197.

Swanson, J. 1978. Studies on gonococcus infection. XIV. Cell wall protein differences
among color/opacity colony variants of Neisseria gonorrhoeae. Infection and Immunity
21:292-302.

198.

Swanson, J., O. Barrera, J. Sola, and J. Boslego. 1988. Expression of outer membrane
protein II by gonococci in experimental gonorrhea. The Journal of Experimental
Medicine 168:2121-2129.

124
199.

Tajima, T., N. Yokota, S. Matsuyama, and H. Tokuda. 1998. Genetic analyses of the
in vivo function of LolA, a periplasmic chaperone involved in the outer membrane
localization of Escherichia coli lipoproteins. FEBS Letters 439:51-54.

200.

Tanaka, K., S. I. Matsuyama, and H. Tokuda. 2001. Deletion of lolB, encoding an
outer membrane lipoprotein, is lethal for Escherichia coli and causes accumulation of
lipoprotein localization intermediates in the periplasm. Journal of Bacteriology 183:65386542.

201.

Tettelin, H., N. J. Saunders, J. Heidelberg, A. C. Jeffries, K. E. Nelson, J. A. Eisen,
K. A. Ketchum, D. W. Hood, J. F. Peden, R. J. Dodson, W. C. Nelson, M. L. Gwinn,
R. DeBoy, J. D. Peterson, E. K. Hickey, D. H. Haft, S. L. Salzberg, O. White, R. D.
Fleischmann, B. A. Dougherty, T. Mason, A. Ciecko, D. S. Parksey, E. Blair, H.
Cittone, E. B. Clark, M. D. Cotton, T. R. Utterback, H. Khouri, H. Qin, J.
Vamathevan, J. Gill, V. Scarlato, V. Masignani, M. Pizza, G. Grandi, L. Sun, H. O.
Smith, C. M. Fraser, E. R. Moxon, R. Rappuoli, and J. C. Venter. 2000. Complete
genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:18091815.

202.

Theil, E. C. 1987. Ferritin: structure, gene regulation, and cellular function in animals,
plants, and microorganisms. Annual Review of Biochemistry 56:289-315.

203.

Thomas, C. E., and P. F. Sparling. 1996. Isolation and analysis of a fur mutant of
Neisseria gonorrhoeae. Journal of Bacteriology 178:4224-4232.

204.

Tokuda, H. 2009. Biogenesis of outer membranes in Gram-negative bacteria.
Bioscience, Biotechnology, and Biochemistry 73:465-473.

205.

Tokuda, H., and S. Matsuyama. 2004. Sorting of lipoproteins to the outer membrane in
E. coli. Biochimica et Biophysica Acta 1694:IN1-9.

206.

Unemo, M., and W. M. Shafer. 2011. Antibiotic resistance in Neisseria gonorrhoeae:
origin, evolution, and lessons learned for the future. Annals of the New York Academy of
Sciences 1230:E19-28.

207.

van der Ley, P., J. E. Heckels, M. Virji, P. Hoogerhout, and J. T. Poolman. 1991.
Topology of outer membrane porins in pathogenic Neisseria spp. Infection and Immunity
59:2963-2971.

208.

van Putten, J. P. 1993. Phase variation of lipopolysaccharide directs interconversion of
invasive and immuno-resistant phenotypes of Neisseria gonorrhoeae. The EMBO Journal
12:4043-4051.

209.

Van Slyke, C. J., R. C. Arnold, and M. Buchholtz. 1943. Penicillin Therapy in
Sulfonamide-Resistant Gonorrhea in Men. American Journal of Public Health and the
Nation's Health 33:1392-1394.

125
210.

Vieusseaux, M. 1805. Memoire sur la maladie qui a regne a Geneve au printemps de
1805. J Med Chir Pharmacol 11:163.

211.

Virji, M., J. R. Saunders, G. Sims, K. Makepeace, D. Maskell, and D. J. Ferguson.
1993. Pilus-facilitated adherence of Neisseria meningitidis to human epithelial and
endothelial cells: modulation of adherence phenotype occurs concurrently with changes
in primary amino acid sequence and the glycosylation status of pilin. Molecular
Microbiology 10:1013-1028.

212.

Virji, M., S. M. Watt, S. Barker, K. Makepeace, and R. Doyonnas. 1996. The Ndomain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria
meningitidis and Neisseria gonorrhoeae. Molecular Microbiology 22:929-939.

213.

Vonder Haar, R. A., M. Legrain, H. V. Kolbe, and E. Jacobs. 1994. Characterization
of a highly structured domain in Tbp2 from Neisseria meningitidis involved in binding to
human transferrin. Journal of Bacteriology 176:6207-6213.

214.

Voulhoux, J. R., and J. Tommassen. 2002. Transport of lipoproteins to the cell surface
in Neisseria meningitidis, Thirteenth International Pathogenic Neisseria Conference Oslo,
Norway.

215.

Wagegg, W., and V. Braun. 1981. Ferric citrate transport in Escherichia coli requires
outer membrane receptor protein FecA. Journal of Bacteriology 145:156-163.

216.

Wall, D., and D. Kaiser. 1999. Type IV pili and cell motility. Molecular Microbiology
32:1-10.

217.

Wally, J., P. J. Halbrooks, C. Vonrhein, M. A. Rould, S. J. Everse, A. B. Mason, and
S. K. Buchanan. 2006. The crystal structure of iron-free human serum transferrin
provides insight into inter-lobe communication and receptor binding. The Journal of
Biological Chemistry 281:24934-24944.

218.

Wan, W. L., G. C. Farkas, W. N. May, and J. B. Robin. 1986. The clinical
characteristics and course of adult gonococcal conjunctivitis. American Journal of
Ophthalmology 102:575-583.

219.

Wandersman, C., and P. Delepelaire. 2004. Bacterial iron sources: from siderophores
to hemophores. Annual Review of Microbiology 58:611-647.

220.

Wang, J., S. D. Gray-Owen, A. Knorre, T. F. Meyer, and C. Dehio. 1998. Opa
binding to cellular CD66 receptors mediates the transcellular traversal of Neisseria
gonorrhoeae across polarized T84 epithelial cell monolayers. Molecular Microbiology
30:657-671.

221.

Wang, J., and K. Pantopoulos. 2011. Regulation of cellular iron metabolism. The
Biochemical Journal 434:365-381.

126
222.

Webb, D. C., and A. W. Cripps. 1999. Immunization with recombinant transferrin
binding protein B enhances clearance of nontypeable Haemophilus influenzae from the
rat lung. Infection and Immunity 67:2138-2144.

223.

Weel, J. F., and J. P. van Putten. 1991. Fate of the major outer membrane protein P.IA
in early and late events of gonococcal infection of epithelial cells. Research in
Microbiology 142:985-993.

224.

Wen, K. K., P. C. Giardina, M. S. Blake, J. Edwards, M. A. Apicella, and P. A.
Rubenstein. 2000. Interaction of the gonococcal porin P.IB with G- and F-actin.
Biochemistry 39:8638-8647.

225.

West, D., K. Reddin, M. Matheson, R. Heath, S. Funnell, M. Hudson, A. Robinson,
and A. Gorringe. 2001. Recombinant Neisseria meningitidis transferrin binding protein
A protects against experimental meningococcal infection. Infection and Immunity
69:1561-1567.

226.

West, S. E., and P. F. Sparling. 1987. Aerobactin utilization by Neisseria gonorrhoeae
and cloning of a genomic DNA fragment that complements Escherichia coli fhuB
mutations. Journal of Bacteriology 169:3414-3421.

227.

West, S. E., and P. F. Sparling. 1985. Response of Neisseria gonorrhoeae to iron
limitation: alterations in expression of membrane proteins without apparent siderophore
production. Infection and Immunity 47:388-394.

228.

Wetzler, L. M., M. S. Blake, K. Barry, and E. C. Gotschlich. 1992. Gonococcal porin
vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from
rmp deletion mutants. The Journal of Infectious Diseases 166:551-555.

229.

Whittington, W. L., and J. S. Knapp. 1988. Trends in resistance of Neisseria
gonorrhoeae to antimicrobial agents in the United States. Sexually Transmitted Diseases
15:202-210.

230.

WHO. 2005. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a
three-year experience. Weekly Epidemiological Record 37:313-320.

231.

WHO. 2001. Global prevalance and incidences of selected curable sexually transmitted
infections: overview and estimates.

232.

Wiesner, P. J., E. Tronca, P. Bonin, A. H. Pedersen, and K. K. Holmes. 1973.
Clinical spectrum of pharyngeal gonococcal infection. The New England Journal of
Medicine 288:181-185.

233.

Williams, J. 1982. The evolution of transferrin. Trends in Biochemical Sciences 7:394397.

127
234.

Williams, J., N. D. Chasteen, and K. Moreton. 1982. The effect of salt concentration
on the iron-binding properties of human transferrin. The Biochemical Journal 201:527532.

235.

Williams, J., and K. Moreton. 1980. The distribution of iron between the metal-binding
sites of transferrin human serum. The Biochemical Journal 185:483-488.

236.

Wolff, K., and A. Stern. 1995. Identification and characterization of specific sequences
encoding pathogenicity associated proteins in the genome of commensal Neisseria
species. FEMS Microbiology Letters 125:255-263.

237.

Woods, C. R. 2005. Gonococcal infections in neonates and young children. Seminars in
Pediatric Infectious Diseases 16:258-270.

238.

Yakushi, T., K. Masuda, S. Narita, S. Matsuyama, and H. Tokuda. 2000. A new
ABC transporter mediating the detachment of lipid-modified proteins from membranes.
Nature Cell Biology 2:212-218.

239.

Yamaguchi, K., F. Yu, and M. Inouye. 1988. A single amino acid determinant of the
membrane localization of lipoproteins in E. coli. Cell 53:423-432.

240.

Yamauchi, K., M. Tomita, T. J. Giehl, and R. T. Ellison, 3rd. 1993. Antibacterial
activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infection and
Immunity 61:719-728.

241.

Yang, Q. L., and E. C. Gotschlich. 1996. Variation of gonococcal lipooligosaccharide
structure is due to alterations in poly-G tracts in lgt genes encoding glycosyl transferases.
The Journal of Experimental Medicine 183:323-327.

242.

Yazdankhah, S. P., and D. A. Caugant. 2004. Neisseria meningitidis: an overview of
the carriage state. Journal of Medical Microbiology 53:821-832.

243.

Yost-Daljev, M. K., and C. N. Cornelissen. 2004. Determination of surface-exposed,
functional domains of gonococcal transferrin-binding protein A. Infection and Immunity
72:1775-1785.

244.

Young, J. D., M. Blake, A. Mauro, and Z. A. Cohn. 1983. Properties of the major outer
membrane protein from Neisseria gonorrhoeae incorporated into model lipid membranes.
Proceedings of the National Academy of Sciences of the United States of America
80:3831-3835.

245.

Zimmermann, L., K. Hantke, and V. Braun. 1984. Exogenous induction of the iron
dicitrate transport system of Escherichia coli K-12. Journal of Bacteriology 159:271-277.

128

Vita

Meredith Lynn Weck was born on June 4, 1988 in Newark, Delaware. She graduated from
Kennett High School in Kennett Square, Pennsylvania in 2006. In the spring of 2010, she
graduated magna cum laude from the University of Richmond with a Bachelor’s degree in
Biology with departmental honors. In the fall of 2010, she began her Master’s degree studies at
Virginia Commonwealth University in the Molecular Biology and Genetics Program and joined
the Department of Microbiology and Immunology in the spring of 2011. Publications and
accomplishments are listed below.

Publications:
Fisher, S. J., M. Weck, J. E. Landers, J. Emrich, S. A. Middleton, J. Cox, L. Gentile, and C. A.
Parish. 2012. Evidence that the kinesin light chain domain contains tetratricopeptide repeat
units. Journal of Structural Biology 177:602-612.

Awards and Honors:
Charles C. Clayton Award 2011-2012
Outstanding Scholarly Achievement, Molecular Biology and Genetics Cirriculum, Virginia
Commonwealth University School of Medicine, Richmond, Virginia
Phi Kappa Phi Fall 2011
Scholastic Honor Society, Virginia Commonwealth University, Richmond, Virginia

